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The research presented in this dissertation was written with either intent to publish 
or is already published in a scientific journal.  The previously published manuscripts were 
modified to meet formatting guidelines.  This dissertation features and introduction on 
glycoprotein purification, current methods and technology (Chapter 1), the experimental 
results of this research project with discussion and methods (Chapters 2-5), and 
conclusions of this dissertation along with recommendations on directions for future 
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Effective methods for isolation and purification of glycoproteins are of increasing 
significance to the rapidly growing biopharmaceutical and diagnostic industry.   
Glycoproteins represent the majority of therapeutic proteins on the market and are 
effectively used to treat immune disorders, infections, cancers, and other diseases.  
Targeting these glycoproteins is also critical to an emerging field of glycoproteomics 
aimed to understand structure-function relationships of glycans.  Architecturally, these 
glycoproteins are proteins with covalently linked oligosaccharide chains of varying 
monosaccharide composition.  Affinity chromatography has proven to be an excellent 
method of glycoprotein purification at the bench scale.  However, chromatography in 
large scale production has its drawbacks.  Column fowling, flowrate limitations, and 
diffusional constraints collectively hinder the effectiveness of the method.  An alternative 
proposed in this dissertation is the use of affinity precipitation as a purification technique.  
The three main objectives are 1) develop and produce dual-functional, thermo-responsive 
affinity ligands from a biological host, 2) characterize and optimize the accompanying 
affinity precipitation method, and 3) apply the ligand and process to relevant, unmodified 
glycoproteins. 
 The design of the thermo-responsive affinity construct was comprised of two 
main functional domains.  The binding capability was achieved by selection of small 
ligands with affinity to a specific monosaccharide moiety.  Two different lectins, or sugar 
binding proteins, were used in the fusion design: a fucose binding lectin from Ralstonia 




responsive functionality was obtained by use of an elastin-like peptide (ELP), which 
confers inverse solubility relationship properties to the fusion construct.  A small library 
of varying ELP chain lengths were designed to find the optimal size fusion for both 
production and function.  These dual functional ligands were cloned and expressed in the 
microbial host, E. coli.  Furthermore, secretion of these constructs was achieved by 
employing the Tat secretion pathway in combination with an outer membrane lipoprotein 
deletion mutant with a leaky periplasm phenotype.  This secretory mechanism allows for 
easy isolation, avoidance of inclusion bodies, and no additional protease inhibitors. 
 After successful production, the ligands were tested to confirm that dual 
functionality was preserved in fusion form.  Once binding conditions and precipitation 
properties were ascertained, the purification ability was tested on model glycoproteins.  
Experimentation was carried out monitoring the purification yield, purity, and retained 
activity of the target enzymes.  High contaminant solutions, such as cell lysates, were 
spiked with the model glycoproteins to mimic crude protein solutions.  The purification 
ability of the constructs in these models was observed. 
 The method was then implemented on two relevant glycoprotein applications: 1) 
purification of soybean peroxidase from a crude protein extract and 2) targeting the 
therapeutic protein erythropoietin from albumin rich, used CHO cell media.  By 
implementation of the fucose targeting fusion construct, the unmodified soybean 
peroxidase is isolated from a natural crude extract from the soybean hull, a by-product of 
the soybean industry.  The affinity precipitation method parameters were optimized with 




of the low abundance enzyme.  Under the optimized conditions, >95% recovery yield and 
a purification of 22.7 fold of an active, pure product was attainable.   
The purification of erythropoietin led to additional experimentation with high-
abundant glycoprotein solutions, as well as expansion of the affinity ligand platform.  
The concept of multi-lectin affinity precipitation, using the fucose and sialic acid binding 
lection sequentially, was introduced and tested for purification capability.  An industrially 
relevant scheme involving isolation of the erythropoietin from used CHO cell media 
allowed for an achievable yield of about 60%, with a resulting albumin depletion of about 
85%. 
In addition to development of a pair of novel thermo-responsive affinity ligands 
for glycoprotein purification, this dissertation provides insight on possible improvements 
and future directions with respect to the thermo-responsive affinity ligand platform.  This 
unique concept employs novel lectin fusions to target valuable glycoproteins using a 






1.1 Glycoprotein Purification Applications 
 Glycoproteins are conjugated proteins containing covalently bonded 
carbohydrates to the amino acid backbone.  The study of glycoconjugates has quickly 
expanded to cover almost all biochemical processes in living organisms, and 
glycosylation is regarded as the most frequent and most diverse post translational 
modification
1–3
.  Specifically, glycoproteins have been found as essential factors in 
processes such as immune defense, fertilization, cell adhesion, and inflammation
4
.  More 
than 50% of eukaryotic proteins are glycosylated
5
.  Furthermore, glycoproteins are often 
used as biomarkers for certain diseases, such as rheumatoid arthritis, cystic fibrosis, or 
various cancers
6–8
, and the field of glycomics, the study of these carbohydrates 
compositions, has emerged.  With this range of study, it is clearly beneficial in many 
areas to isolate and target these glycoproteins, both for further characterization as well as 
glycoprofiling and activity determination.  Thus, many methods of glycoprotein 
purification have been experimentally pursued to purify a range of different glycoproteins 
for different applications. 
 
1.1.1 Therapeutic Protein Purification 
 Over 70% of the therapeutic protein drugs on the market are classified as 
glycoproteins
9




pharmaceutical industry, and include several categories of drugs, such as monoclonal 
antibodies, enzymes, blood factors, and hormones
10
.  It has even been estimated over 
30% of new drugs licensed throughout the next ten years will be antibodies and antibody 
derivatives
4,11
.  While these protein therapeutics generate a 30 billion dollar industry, 
these high demand drugs are expensive to produce.  The high cost, however, is primarily 




 Typically, the downstream process is comprised of three mains phases of 
preparation: clarification, purification, and formulation
13
.  While clarification and 
formulation are required steps in all fermentation based production processes, the 
purification phase is specific to the desired target.  In the case of protein therapeutics and 
most drug products, purification is the bottleneck in terms of cost, energy, complexity, 
and specification requirements
14,15
.  The purification technology has yet to meet the 
demand of these drugs, but the currently implemented standard is chromatography.  
While various types of chromatography are often employed, such as size exclusion 
chromatography or anion exchange chromatography, the most relied upon methodology 
for targeting specific glycoproteins is affinity chromatography
16,17
. 
1.1.1.1 Purification Methods 
 Affinity chromatography has proven to be the most ideal to date, as it utilizes high 
specificity and attempts to avoid denaturing the target therapeutic protein by exposure to 
low pH or high salt conditions.  To obtain this high specificity, it exploits the use of 
affinity ligands.  These affinity ligands are typically proteins that have a high binding 




clarified crude protein solution to be flushed through the column while the target remains 
bound to the ligand.  The target is then eluted from the column using an elution buffer.  
The use of these affinity ligands allows for the most ideal targeting of a specific product.  
In current industrial purification schemes, Protein A and Protein G are by far the most 
widely used ligands.
12,18





 range, these have been the gold standard for targeting immunoglobulin G species 
and other monoclonal antibodies. 
1.1.1.2 Importance of Glycan Recognition 
 However, isolation of a target glycoprotein is not the whole story.  As specific 
isoforms of glycans have been noted to enhance protein stability, extend therapeutic half-
life, modulate biological activity, and increase efficacy, it is imperative the final drug 
product contain the correct isoform and composition of glycan
19,20
.  Different isoforms 
can be produced by variation in culture conditions.  For example, osmolality levels as 
well as culture duration contribute to increased levels of mannose-5 glycoform of 
antibodies in Chinese hamster ovary (CHO) cell production
21
.  This leads reduced 
efficacy of the antibodies, as mannose-5 glycoforms are found in very low amounts in the 
body. 
 Glycoproteins can range from 1-90% in carbohydrate composition
3
.  There are 8 
common glycan residues, each of which could be further derivatized.  Furthermore, the 
glycosidic linkages can be formed between any of the hydroxyl groups, leading to 
numerous configurations and linkages.  For example, four different monosaccharides 
could link a variety of ways and form 35,560 unique tetrasaccharides
22
.  Unlike proteins 




microheterogeneity leads to many glycoforms present in a solution, and must be 
addressed when producing a pure and efficacious drug product.  An example of this 








The purification process must, in turn, target a single glycoform.  Because of this 
additional complexity, affinity chromatography is not sufficient as a single method of 
purification.  As described earlier, affinity chromatography procedures currently used 
industrially purify by exploiting the binding properties between ligand and polypeptide 
backbone.  However, this does not discern amongst glycoforms.  Additional purification 
methods, such as anion exchange and size exclusion chromatography, must be 
implemented to yield a single isoform of the desired therapeutic product. 
 
1.1.2 Crude Enzyme Purification 
 Many clinically and industrially useful glycoproteins are extracted from natural 
sources.  In order to foster a “green” economy, biosciences must find new ways to target 
and apply natural sources to more products and services
24,25




required for identifying new and useful glycoproteins from crude sources from plants, 
animal serums, fungi, and bacteria.  Specifically, such useful glycoproteins include 
peroxidases, which are used for a myriad of industrial or laboratory applications. 
 One of the more commonly used peroxidases is one isolated from horseradish 
roots.  It is the most widely studied member of the peroxidase enzyme family EC 
1.11.1.7, and has been applied to many biosensing and diagnostic applications
26
.  As a 
biotechnological tool, horseradish peroxidase (HRP) is invaluable in ELISA assays and 
bioremediation, so much effort has been put into extraction and purification of the 
valuable glycoprotein.  Early purification methods still prevail; processes include 
ammonium sulfate precipitation followed by chromatographic methods, such as ion-
exchange, size exclusion, or affinity chromatography.  This combination of techniques 
was used in the 1960’s and is used today
27
.  Although column chromatography 
technology has improved, it often requires very costly set-ups, as addressed in section 
1.2.1.  Other methods have been pursued, such as aqueous two-phase partitioning, with 
varying results
28
.  However, as the buffer in which the HRP is stored can increase the 
sensitivity of the HRP thermal stability, caution must be taken with the solvents chosen
29
.  
These alternative solvent methods also require large amounts of water that is wasted, 
rendering them relatively inefficient.  In order to purify HRP on the order of magnitude 
required for large applications, such as wastewater treatment, other alternatives must be 
considered
30
.  Also, the relatively poor stability of this enzyme limits the purification 
methods that can be applied. 
 Where HRP has a long standing reputation as a useful tool, a less traditional 






.  SBP is a peroxidase isolated from the hull, or seed coat, of 
soybeans.  As the hulls are an inexpensive by-product of soybean processing, this enzyme 
already lends itself credence in decreased cost of raw material
33
.  This soybean 
peroxidase (SBP) has shown promising thermal and pH stability where HRP has not.
34,35
  
With a large pH range of 2.4-12 and a melting temperature of 90.5˚C, SBP has the 
potential to bypass the current popularity of HRP to become a very useful enzyme
36
.  
This stable enzyme can easily be applied as a catalyst for phenolic resin synthesis, an 
indicator for food processing, a diagnostic component, an additive for bioremediation, or 




1.1.3 Monosaccharide Significance 
 Glycans are typically comprised of eight common monosaccharides, shown below 
in Table 1.1.  All are very similar in composition.  In the case of glucose, mannose, and 
galactose, the only different is the confirmation of a hydroxyl group.  Alterations of these 
monosaccharides in a glycan directly affect the metabolic fate of the glycoprotein, as well 
as possible structure-function relationships
3
.   
As glycans are involved in cell-cell recognition, a change in monosaccharide 
composition also relates to adhesion and pathogenicity
41
.  Additionally, “changes in 
glycosylation are often a hallmark of disease states” 
42
, so identification, progression, and 
treatment often directly link to the presence and abundance of certain monosaccharides.  
By designing a system that targets a specific monosaccharide, not only is there 
enrichment of low abundance glycoproteins, but there is fractionation toward a specific 




method aids in biomarker discovery and therapeutic protein purification.  Specifically, 
two lesser abundant carbohydrate moieties, fucose and sialic acid, were used as target 
monosaccharides. 
Table 1.1 The most common monosaccharides found in glycans and their size
40
. 
Common Monosaccharides Abbreviation Residue Mass (g/mol) 
Glucose Glc 180.16 
Galactose Gal 180.16 
Mannose Man 180.16 
Fucose Fuc 164.16 
Acetylgalactosamine GalNAc 221.21 
Acetylglucosamine GlcNAc 221.21 
Acetylneuraminic acid NeuNAc 309.27 
Xylose Xyl 150.13 
 
1.1.3.1 Fucose 
 Fucose is a deoxy hexose monosaccharide present in the oligosaccharide chains of 
many glycans and glycolipids. Though it’s not the most abundant oligosaccharide, its 
function and presence are important in adhesion, host-microbe interactions, signaling, 
inflammation, and many ontogenic events
6,43,44
. Terminal glycan fucosylation is common 
and can confer unique properties for cell differentiation.  Aberrant fucosylation is also 
linked with as many as 18 diseases. Fucose has become an important biomarker for many 




disease, cystic fibrosis, and asthma
45,46
.  In antibodies, the structure of glycans N-linked 
to immunoglobulin G (IgG) molecules is often core-fucosylated, typically via α1,3 or 
α1,6 linkages
47,48
.  Sometimes, antibodies should be isolated based on their fucosylation.  
For example, Antibody Dependent Cellular Cytotoxicity is increased 100 fold when IgG4 




1.1.3.2 Sialic acid 
 Sialic acid, or N-acetylneuraminic acid, is a larger monosaccharide comprised of 
a 9 carbon backbone and an acetyl group that confers a negative charge to the molecule.  
Even as a less abundant monosaccharide, it is of great physiological and pathological 
importance.  It is typically found at the terminal position of glycans on animal 
glycoconjugates and is thought to have appeared late in evolution
49
.  It is also the most 
diversely substituted natural sugar
50
.  Sialic acid, like fucose, contributes to the high 
viscosity of mucins, is often found in membranes, and is often involved in pathogenic 
recognition.  However, because it’s a unique target monosaccharide, it is also used in 
anti-recognition effects resulting in the masking of penultimate sugars
51
.  Unfortunately, 
over sialylated malignancies are often masked as well, keeping them protected from 
cellular defense systems.  In vivo, sialic acid is also used for cell-cell recognition.  For 
example, red blood cells having lost 10-20% of their surface sialic acids are targeted, 
degraded, and expelled from the body. 
 Because of the importance of sialic acid residues, extensive studies of sialylated 
glycoproteins and their glycoforms have been researched.  It’s been shown that additional 




properties of certain glycoproteins
20,52
.  Specifically, analysis of the therapeutic protein 
erythropoietin (EPO) illustrates the role sialic acid plays in biosynthesis, secretion, 
expression, and, mainly, biological activity.  Removal of the terminal sialic acids result in 




1.2 Affinity Precipitation 
To attempt to circumvent the pitfalls associated with affinity chromatography, 
affinity precipitation has become an increasingly investigated technique. As the name 
suggests, affinity precipitation exploits the same target specific ligands, but avoids ligand 
immobilization and chromatographic methods.  Affinity precipitation is achieved by 
utilization of the affinity ligand bound to a stimulus responsive polymer.  As the binding 
step of the ligand to the target protein is done in aqueous conditions, diffusional 
limitations and steric hindrance are minimized. The ligand bound target complex is then 
precipitated out of solution via the environmentally stimulated polymer.  This yields a 
precipitate containing the ligand, target, and some non-specific precipitates.  The soluble 
contaminants are removed, and the precipitate is resolubilized.  The reversibility of 
precipitation makes the tool recyclable, reducing the cost of materials. It is also very 
scalable, especially when compared to affinity chromatography, which makes it a viable 
candidate for large scale processes. 
 




Affinity chromatography has proved an excellent method of glycoprotein 
purification at bench scale processes.  However, chromatography in large scale 
production has its drawbacks. Column fowling, flowrate limitations, and diffusional 
constraints collectively hinder the effectiveness of the purification process
17,53
. The 
biological component, such as Protein A, is expensive, sensitive to cleaning solutions, 
and sometimes leaks from the matrix into the product, requiring further purification steps 
downstream
18
.  Furthermore, high water usage in flow through, multiple washing steps, 
and elution steps augment the cost and waste of the process
54
.  Because of these 
shortcomings, affinity chromatography proves to be a very costly and insufficient method 
of purification when scaled up.  Alternative methods of purification, preferably avoiding 
chromatographic methods, are currently in investigation.  Affinity precipitation is a 
promising substitute. 
 
1.2.2 Alternative Precipitation Methods 
 Precipitation as a method of purification is not a new concept, especially in 
relation to proteins.  As misfolding and aggregating proteins is relatively simple to do, 
it’s long been experimented with as a method of purification.  A common example is 
ammonium sulfate precipitation, which is widely used and is easy to scale up
53
.  Also, 
solid-liquid separation is straight forward and well-understood, which makes 
precipitation quite desirable, especially at the industrial scale.  As different protein have 
differing ionic strengths, the salting-out method of altering the ionic properties of the 
solvent has been a quick and simple process.  Sequential precipitation has even been 




precipitation methods, such as acetone and caprylic acid precipitation, have also been 
explored.  However, the main pitfall of all these methods is the lack of specificity.  They 
are not always amenable for efficiently targeting a specific isoform or glycoform. 
 In an effort to develop a more specific purification system, affinity macroligands 
were synthesized.  These affinity macroligands had dual functionality: an affinity domain 
and a stimulus responsive region.  The first attempt at this was a copolymer of 
acrylamide, N-acryloyl-p-aminobenzoic acid, and N-acryolyl-m-aminobenzamidine
55,56
.  
The benzamidine units also acted as affinity ligands to target enzymes.  However, the 
environmental stimulus required for purification was a decrease in pH to 4, which often 
hindered the activity of the target enzyme. 
 Another attempt was the design of a Eudragit S-100 responsive ligand.  Eudragit 
S-100 is a copolymer of methacrylic acid and methyl methacrylate and also has pH 
dependent solubility
57,58
.  This ligand was chemically fused to an affinity ligand, 
specifically the antigen of the IgG monoclonal antibody, and precipitated by lowering the 
pH to 4.8.  Centrifugation was used to separate the pellet, and the purified product was 
analyzed.  This procedure yielded a purification of 68.4%, with antibody activity lost due 
to inactivation. 
 
1.2.3 Current Affinity Precipitation Methods 
 Affinity precipitation also improves the overall process of therapeutic protein 
separations by enhancing process integration, which can potentially save on energy, 
materials, and time.  After fermentation, clarification of the fermentation mixture is 




viscosity for the other downstream processing steps. After initial clarification come 
multiple isolation steps, including affinity and size exclusion chromatography. Finally, 
consolidation steps concentrate the target protein from the high dilution steps involved in 
chromatography down to a highly concentrated pure batch of drug substance. The many 
steps involved in the purification and consolidation process each allow for potential loss 
of product, lowering the final yield of pure protein. However, by utilizing affinity 
precipitation, many of these steps can be consolidated into a single step procedure. 
Clarification can be kept to a minimum, as the affinity ligand can be added to a crude 
solution. The purification of the technique is inherent, and though other purification steps 
may be needed for virus clearance, it eliminates the need for multiple chromatographic 
steps.  Also, as the product of affinity precipitation is initially a solid precipitate, 
resuspension in a smaller amount of liquid for solubilization dramatically aids in the 
consolidation step. Thus, affinity precipitation aids in all three major sections or 
therapeutic protein purification.  Consolidation of this process not only has the potential 
to save time and money, but often rapid purification aids in maintaining stabilization, 
improving the active yield. 
 
1.2.4 Elastin-Like Proteins (ELPs) 
 One particularly useful biopolymer used in affinity precipitation is Elastin-Like 
Proteins (ELPs). Originally derived from mammalian elastin, ELPs are composed of a 
repeating pentapeptide sequence Val-Pro-Gly-Xaa-Gly, where the fourth position, Xaa, is 
a guest residue that can be substituted by any naturally occurring amino acid except 
proline
59,60




transition temperature Tt, above which the polymer becomes insoluble
61–64
.  This inverse 
phase transition behavior can be manipulated and applied to many areas in 
biotechnology, such as non-chromatographic purification, drug delivery, tissue 
engineering, responsive hydrogels, and biosensing
65,66
. 
 The responsiveness of an ELP peptide is affected, at the molecular level, by the 
hydrophobicity of the guest residue and the total length of the peptide. Alteration of the 
guest residue has been studied extensively, with variations in both the guest amino acids 
and fractions at which they appear in the total peptide. This deviation manifests as a very 
distinct, almost predictable change in transition temperature. This resulting change in 
transition temperature has even been used as a measure of the hydrophobicity of residues 
respectively
59,61
. This hydrophobicity scale is formed on the basis of an increase in 
transition temperature when the pentapeptide contains a more hydrophobic residue, 
where, conversely, a more hydrophilic residue yields a lower transition temperature. This 
tunable nature is also based on the length of the resulting peptide. An extended chain of 
pentapeptide repeats in the sequence decreases the transition temperature. 
 After these intrinsic factors have been specified, the phase behavior then becomes 
a dependent on other solution conditions, such as pH, salt concentration, and 
concentration of the peptide in solution
65
. Predictive models on this variation in phase 
transition have been done for various constructs of ELPs, and the behavior at variable 
conditions is fairly well understood. 
 As suggested by the relation to hydrophobicity, the ELP solubility is related to the 
secondary structure of the protein and the hydration state
67–70
.  Below the transition 




more compact, due to an increased number of intramolecular hydrogen bonds
64
.  At this 
lower hydration state, the protein precipitates, albeit differently than that of standard 
protein denaturation. By lowering the temperature again, the entropically driven process 
unfolds, rehydrates, and becomes soluble once more.  Fusion of ELPs has been 
implemented in an effort to use this unique inverse transition state for protein purification 
purposes. 
1.2.4.1 ELP Tags 
 At the transcriptional level, ELP biopolymer has been experimentally fused to the 
gene corresponding to the protein of interest, typically on a plasmid.  This ELP tag 
confers the phase transition properties to the target protein, so the target can be isolated 
by environmental stimulus.  Both soluble and insoluble proteins, such as thioredoxin and 
tendamistat respectively, have been fused with ELP tags in microbiological hosts and 
efficiently harvested from cultures
71–74
.  This demonstrates the versatility of the tags in 
relation to aiding in solubility as well as purification.  The fusion proteins display 
retained activity inspite of the ELP fusion, suggesting functionality is not lost.  Fusion 
order has been investigated, and has been noted to sometimes effect the expression of the 
fusion protein
75
.  Expression of these fusion proteins in E. coli has been further optimized 
to increase production of these larger constructs
73,76
.  This fusion method is not limited to 
microbes, but as also been investigated in molecular farming techniques.  An ELP tag on 
biologically active glycoprotein 130, GFP, erythropoietin, and interleukin-10, amongst 
others, have been successfully expressed in transgenic tobacco plants
77–79
.  The ELP tag 
allows for an easy purification step, allowing for dramatic reduction of undesirable 




However, in most practical applications, a purified protein containing an additional tag is 
undesirable.  The ELP must be removed from the desired product.  However, many 
chemical cleaving mechanisms require harsh chemicals, compromising the folding and 
activity of the desired protein in the process.  Proteolytic methods are costly, as addition 
enzymes are required.  So in order to address this obstacle, a few solutions have been 
introduced. 
1.2.4.2 ELP Intein Fusions 
 The first solution to address the removal of the ELP tag from the target protein 
was implementation of a self-cleaving intein fusion between the ELP fusion and the 
protein of interest.  An intein is a protein containing an endonuclease and splicing 
sequence that is self-cleaving upon pH variation
80
.  Mini inteins have been developed and 
used as fusions for the purpose of affinity tag addition and removal.  Target proteins have 
target-intein-tag domain conformations, where the affinity tag is a moiety that can be 
targeted via affinity chromatography, such as maltose binding protein
81,82
.  However, as it 
is desirable to shift away from affinity chromatography, this affinity tag can be replaced 
with other mechanisms of purification, such as an ELP functional domain.  Dr. Wood’s 
lab, amongst others, has designed a variety of these intein-ELP fusion proteins, in both 
microbial and mammalian hosts
72,83–86
.  While functional and very efficient, it is still 
required that the protein of interest are recombinant and transcriptionally fused to these 
domains, which is not always a viable route.  This requires additional cloning, plasmid 
maintenance, and expression optimization.  Furthermore, this approach cannot be used 




recombinant target.  Other approaches must be investigated in increase the range of 
applicability. 
1.2.4.3 ELP Fused to Affinity Tags 
 Instead of ELP fusion to the protein of interest, a different approach has evolved 
that expands the applicability of the ELP purification scheme.  An ELP fusion to an 
affinity tag still exploits the inverse temperature properties of the ELP while maintaining 
the specificity achieved by using an affinity tag
87–89
.  This technique is similar to the 
Eudragit S-100 technique; however, the ELP functionality allows for different stimuli to 
facilitate precipitation.  Instead of requiring a low pH, which often denatures sensitive 
therapeutic glycoproteins, a change in salt concentration, temperature, or combination of 
the two is the initiating factor for precipitation. 
Figure 1.2 Schematic of purification method using an ELP-affinity construct. 
 
Using this method, simplified steps and solid liquid separation are used to target a 










the affinity end, the ELP-affinity fusion construct binds to the target.  The precipitation of 
the ELP is then achieved by some external stimuli, transitioning the protein of interest to 
the solid state.  Finally, the ELP-affinity ligand and target protein are reimbursed in a 
new solution and solubilized.  After release, the ELP-affinity ligand is again isolated, 
leaving a solution containing only the target protein. 
Furthermore, instead of an additional fusion step, the entire construct is produced 
in a bacterial host, so no additional chemical steps or lost ligand are required.  While this 
is more of an economic advantage, it’s also a benefit in consolidation of the process: 
where production and isolation can be done without any extra steps. 
 
1.3 Lectins 
Sugar binding proteins, called lectins, have emerged as vital tools for 
identification, purification, and structural analysis of complex carbohydrates and glycans.  
More than 300 lectins have been discovered, most of which are plant-based in origin
90
.  
However, lectins have been discovered in animals, microorganisms, and viruses as 
well
91,92
.  Lectins function biologically as cell-surface receptors, cell adhesion, and 
glycan synthesis control
22,93
. They are thought to play an important role in the immune 
system as well, particularly in pathogen recognition. Typically multimeric in structure, 
their superb binding capacity (10
-6
 M) has made lectins key players in glycomics and 
protein purification
94
. Although non-enzymatic in function, they recognize mono- and 





1.3.1 Lectin Technology 
Because of their unique sugar targeting properties, lectins have been employed in 
various constructs of biomolecular analytical methods.  Specifically, lectins are used as 
tools to target specific glycan compositions.  Lectinosorbent assays, lectinoblotting, and 
biotinylated lectins have all been used for characterization and quantitation of 
glycoconjugates
95,96
.  Lectin microarrays have aided tremendously in glyco-profiling, and 
have given rise to new high-throughput techniques
90,97
.  However, for glycoprotein 
enrichment and isolation, it is lectin affinity chromatography that has emerged as a key 
player in glycomics
98
.  Lectin affinity chromatography has been successfully utilized for 
biomarker detection, diagnostics, and characterization, as well as larger scale downstream 
processing
15,98,99
.  Immobilization of lectins on a column allow for higher throughput of 
sample under benign conditions, enabling capture of glycoproteins containing specific 
sugar moieties.   
 
1.3.2 Multi-lectin Affinity 
In addition to lectin affinity chromatography, a novel technique of interest is the 
implementation of multiple types of lectins immobilized on a column, called multi-lectin 
affinity chromatography (M-LAC).  By combining the affinity of different lectins to 
different respective carbohydrates, the target can be defined by more than a single 
monosaccharide composition.  In fact, this method allows for screening of glycoproteins 
with known glycosylation patterns.  In some cases, as many as 5 different lectins were 
chosen to selectively capture different glycoproteins in a biological sample
100
.  




abundance glycoproteins can be depleted
99,101,102
.  Use of this technique allows more 
explicit detection of varying isoforms for the same glycoprotein of interest.  Furthermore, 
this creates a customizable platform for targeting different glycoproteins. 
1.3.3 Bacterial Lectins 
 While plant lectins are often utilized for their interactions with complex glycans 
or internal sugar sequences, bacterial lectins generally bind to terminal monosaccharides. 
Often referred to as adhesion proteins, these lectins are used for attachment to host cells 
and facilitate infection
103
.  Although some lectins are promiscuous in binding, most are 
specific as to linkage of a monosaccharide. Bacterial lectins, as already a product of 
bacterial organisms, are more likely to be compatible with recombinant expression in E. 
coli, due to similar codon and protein usage.  With minimal codon optimization, bacterial 
lectins can be easily duplicated, as no posttranslational modification is necessary. 
However, as many plant lectins are now commercially available, further development and 
utilization of bacterial lectins has not been a large focus. By producing these lectins in E. 
coli¸ higher yields can be obtained in a shorter amount of time than lectin production in 
fungi and plants, making bacterial lectins a cost effective alternative
104
.  Bacterial lectins 
are also generally much smaller than higher organism lectins, which again lends credence 
to compatibility of expression in E. coli. Furthermore, the small size makes these lectins 
optimal candidates for fusion proteins, as smaller, less-bulky proteins are less likely to 
interfere with the other functional domain.  Although these lectins are less popular in the 
current field of lectinology, I chose to pursue fusion and expression of a bacterial lectin, 
and I hope this research stimulates further exploration and manipulation of bacterial 




1.3.3.1 Ralstonia solanacearum Lectin (RSL) 
Based on the importance of fucose and the many prospects associated with 
isolation based on fucosylation, fucose-binding lectins were investigated. There are many 
fucose binding lectins used in monosaccharide identification. A particularly suited lectin 
is one found in the bacteria Ralstonia solanacearum (RSL).  As this lectin originates in 
bacteria, expression in E.coli is more favorable than the expression of a protein natively 
found in a plant or animal. The RSL lectin is also relatively small at only 90 amino acids 
and 10 kD
105
.  It does not require additional metal ions for binding, such as calcium or 
magnesium.  As with many lectins, it forms a homo-oligomer, specifically a homotrimer 
for optimal binding.  It binds preferentially to L-fucose, and preferentially still toward 
α1,6 and α1,2 linkages of fucose to an oligosaccharide chain
106
.  Putatively, this lectin is 
involved in the infectivity of R. solanacaearum, which known to cause lethal wilt in 
plants.  It has 6 binding sites for fucose; 3 are within a monomer (intramonomer), while 3 
are sandwiched between two of the three monomers (intermonomer), as pictured in 
Figure 1.3. This lectin has an affinity for fucosylated oligosaccharaides in the 10
-7
 M 
range, and an affinity for free fucose in the 10
-6
 M range. The binding of fucose is 
primarily a result of hydrogen bonding of amino acids to the hydroxyl groups, but Van 










1.3.3.2 Vibrio cholera Neuraminidase (VCNA) 
As mentioned in section 1.1.3, often the presence of certain monosaccharides 
directly affects the pathogenicity of certain bacteria.  In the case of V. cholera, the 
organism has evolved to remove the abundance of sialic acids present from high order 
gangliosides to reveal the real receptor, GM1
108,109
.  The removal of sialic acid from 
surrounding mucin layers is credited to a secreted neuraminidase enzyme.  This Vibrio 
cholera neuraminidase (VCNA) is comprised of 3 distinct domains: a neuraminidase 
catalytic domain, and two flanking lectin regions
110
.  Of these two lectin domains, the N-
terminal lectin has been found to bind with high affinity to sialic acid (Kd of 30 µM) and 
similar affinity to sialic acid containing substrates, α-2,3-sialyllactose and α-2,6-
sialyllactose
108
.  This 21 kD binding site is efficient in targeting terminal sialic acid 




Figure 1.4, the binding is primarily hydrogen binding with some water molecule 
mediated interactions. 
   
 





1.4 Host Secretion 
In biotechnology, an essential tool for recombinant protein production is the use 
of Escherichia coli.  E. coli is one of the most popular hosts for protein expression as it is 
well characterized, has many inherent known and available expression systems, and is 
relatively easy to manipulate
111
.  However, some major drawbacks are commonly 
associated with expression in E. coli.  Over expressed proteins often form inclusion 




in a loss of activity.  Certain protein cannot be actively expressed at all in E. coli, as 
complex disulfide bonds cannot be formed in the reducing nature of the cytoplasm
112
.  
Conversely, should the protein be translocated to the periplasm, proteolytic degradation 
will likely occur, again reducing total yield of desired protein.  Ideally, extracellular 
secretion of a recombinant protein would suggest greatest yield, as well as avoid the need 
for cell lysis for protein isolation.  This would be ideal in ease of production, which 
logically leads to a reduced cost of the process as a whole.  However, E. coli does not 
have natural, efficient extracellular secretion mechanisms.  This obstacle must be 
addressed to proficiently express the desired recombinant protein and resourcefully purify 
it without using sonication, addition of protease inhibitors, or chromatographic processes.  
Multiple molecular engineering approaches have been taken to try to integrate bacterial 
secretion pathways into E. coli.  Combinations of translocation pathways and increased 
outer membrane permeability have led to some promising options. 
 
1.4.1 Tat Pathway 
Several prokaryotic organisms express secretory proteins by way of signal 
sequence.  A popular design of signal sequence is one harboring a twin-arginine motif, 
designated as the twin-arginine translocation (Tat) pathway.  This characteristic motif is 
typically seen as an N-terminal signal sequence comprised of S-R-R-x-F-L-K residues
113
.  
Another distinct characteristic of this pathway is the ability to translocate fully folded 
proteins across a membrane.  This is dissimilar from other typical mechanisms that, while 
still translocating post-translationally, delay folding until after the transmembrane 




range of protein sizes are amenable with the Tat dependent pathway.  Tat substrates 
encompass roughly 10-100 kDa proteins without inciting addition cytoplasmic leakage
114
. 
However, this signal sequence induced translocation merely moves the desired protein 
across the inner membrane.  Collection of the target protein in the periplasm still leads to 
inclusion bodies and requires additional cell processing.  To complete the process of 
complete extracellular secretion, additional steps must be engineered.  A mutant of E. coli 
strain, designated E609Y, has been engineered with a deletion of the coding for Braun’s 
lipoprotein, resulting in a leaky periplasm phenotype
115
.  Combining this lpp deletion 
mutant with the Tat dependent pathway, recombinant proteins are translocated to the 
periplasm and leaked out into the extracellular milieu.  This has resulted in relatively high 
extracellular expression without the requirement of cell lysis.  In the proposed work, the 
fusion proteins will be produced using a well characterized E. coli expression system.  
Since these fusions are thermal responsive ligands and are used in affinity precipitation, 
the cost of production must be low enough for large scale industrial production.  This 
could be achieved by implementing this extracellular secretion production pathway. 
 
1.4.2 Sec Pathway 
 Another secretion pathway amenable to bacterial protein production in E. coli is 
the Sec pathway. Similarly to the Tat-dependent pathway, an N-terminal signal sequence 
is targeted after translation.  These signal sequences are characteristically comprised of a 
hydrophobic core of ten or more residues flanked by positively charged terminal 
regions
116
.  Once targeted, the protein is translocated, and continues on to either its native 
folded state or outer membrane integration
117




protein secretion.  At least 11 proteins are confirmed to be involved with this secretion 
mechanism, which requires extra metabolic burden on the cell compared to that of the Tat 
pathway, which only requires 3
113
.  However, this method of secretion has been applied 
abundantly to a wide range of biotechnological applications with great success. 
 
1.5 Project Objectives 
The overall goal of this project is to engineer a recombinant thermal responsive 
affinity ligand by combining the carbohydrate binding properties of a lectin with the 
thermal responsive properties of elastin to form lectin-ELP fusion proteins.  These fusion 
proteins will be used to develop a novel thermal responsive affinity precipitation method 
for isolation of glycoproteins from high contaminant solutions.  I propose to engineer 
several fusion proteins by manipulating the size of the ELP fusion, which results in 
changes in the precipitation temperature.  Furthermore, fusion proteins with different 
lectin domains will be engineered, so as to target a variety of monosaccharides found on 
desirable glycoproteins.  These fusion proteins will be produced from an E. coli 
expression system capable of extracellular secretion.  The primary application will be 
glycoprotein purification processes for valuable peroxidases and therapeutic proteins. 
 
1.5.1 Construction and Production 
The synthetic gene encoding these fusion proteins will be created by a 
transcriptional fusion of the lectin to an ELP.  By cloning and expressing the constructs in 




tandem with extracellular secretion, I will illustrate ease of production and isolation from 
a commonly used biological model, E. coli, making this method a cost effective, 
integrated alternative to current separations processes. 
By studying the secretion levels of a range of different sized fusion proteins, the 
benefits and limitations of this previously developed secretion pathway for E. coli will be 
evaluated as a method of large scale protein production for the construct.  Different 
secretion pathways will be investigated, as well as a variety of culture conditions to 
optimize expression. 
 
1.5.2 Ligand Characterization 
The produced fusion protein will be tested for functionality and response based on 
process conditions such as temperature, pH, and salt concentration. The transition 
temperature will be characterized based on these parameters.  The transition temperature 
will be varied to extend the range of application of the construct to high and low 
temperature situations.  The trimer formation of the lectin portion as a function of time, 
temperature, and fucose concentration will be experimentally determined, as well as the 
effect this trimerization has on lectin binding.  The binding parameters will be 
experimentally determined. 
 
1.5.3 Affinity Precipitation Purification Method Optimization 
 Using a fucose-binding lectin as a model affinity ligand, a method of fucosylated 
glycoprotein purification will be developed.  Horseradish peroxidase, a fucosylated 




fusion construct, a method of sialylated glycoprotein purification will be developed.  
Fetuin, a sialylated glycoprotein, will be used as a model protein.  Parameters relevant to 
that purification process such as temperature, target protein concentration, affinity ligand 
concentration, precipitation time, incubation time, and pH will be investigated.  The 
robustness of this new affinity precipitation method will be tested to constraints such as 
low detection limits and high contaminant concentrations.  The recyclability of the fusion 
construct will also be studied.  The two constructs will then be used in tandem to create a 
multi-lectin affinity precipitation technique for glycoproteins containing both fucose and 
sialic acid. 
 
1.5.4 Industrial Application 
 The advantages of this bi-functional protein will be extended to purification of an 
industrially desirable glycoproteins.  Specifically, soybean peroxidase and erythropoietin 
will be isolated from other glycopeptides present in a crude biological sample.  This will 
allow rapid isolation of targeted glycopeptides for further identification.  This is a much 
more focused approach of analysis, potentially leading to a rapid method for biomarker 
identification for potential medical detection applications. 
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DESIGN, CONSTRUCTION, AND PRODUCTION 
2.1 Abstract 
Novel thermo-responsive affinity sugar binders were developed by fusing a 
bacterial fucose lectin with a thermo-responsive polypeptide. These designer affinity 
ligands fusions were produced using an E. coli system capable of extracellular secretion 
of recombinant proteins and were isolated with a high recovery yield (95%) directly from 
growth medium by Inverse Temperature Cycling (ITC).  In this work, we present a 
recombinant thermal responsive affinity ligand by combining the carbohydrate binding 
properties of a lectin with the thermal responsive properties of elastin to form lectin-ELP 
fusion proteins.   
2.2 Introduction 
Protein purification is an essential method required in the biotechnological 
industry, with many different techniques currently used and being developed.  With the 
popularity of recombinant proteins grew the capability of transcriptional fusion proteins.  
Either by plasmid or genomic incorporation, transcriptional fusions have become 
essential in identification, characterization, and purification of many recombinant 
proteins in both eukaryotic and prokaryotic systems.   
Various types of tags are used in research today.  Glutathione S-transferase, 
maltose-binding protein, chitin-binding protein, and biotin tags are affinity tag examples 
often fused to target protein
1.




residues.  Specifically, more than 60% of proteins produced for structural studies include 
a polyhistidine tag
2
.  With this small fusion of amino acids, use of affinity purification 
results in yields of 90% or more.  However, while this small modification is efficient for 
purification, certain scenarios such as clinical application require removal of this tag.  To 
combat expensive or detrimental tag removal processes, new methods exploiting 
endoproteases are employed. 
Typically, a fusion protein is designed at the transcriptional level.  A cloned 
segment of DNA is ligated into a plasmid vector containing the desired codons for the 
affinity tag expression
3.
  Whether this fusion is at the N-terminus or C-terminus of the 
target is dependent on various constraints, such as ease of cloning or folding 
requirements.  Furthermore, a linker is often required, so the additional presence of the 
tag does not interfere with folding or activity of the target protein.  As this fusion gene is 
downstream from a promoter, expression is induced and the fusion gene is produced.  
Expression optimization typically follows to avoid inclusion body formation. 
Expression optimization is essential in structuring to lower the cost of production 
for the desired fusion proteins.  Increased production in a biological host decreases the 
cost when compared to other synthetic and chemical methods.  Changes in growth 
temperature, medium, and induction procedure are all crucial in optimization
4
. 
In this fashion, fusion proteins will be engineered.  However, instead of using 
chromatographic methods, the fusion proteins will contain an environmentally responsive 
tag, so purification is as easy as temperature fluctuation.  These fusion proteins will act as 
the binding ligand to target the native protein of interest, requiring no derivatization of 




extracellular secretion.  We illustrate the bi-functionality of this affinity precipitation 
tool.  
2.3 Results 
2.3.1 Design, Cloning, and Expression of Constructs 
The constructs were carefully designed for functionality, expression, secretion, 
and flexibility for future work.  The synthetic gene was deliberately constructed to allow 
for oligomerization of the ELP segment so further optimization of the fusion could be 
performed.  Additional functionalities, such as signal peptides, fusion order, and linkers 
were investigated as well.   
2.3.1.1 RSL-ELP20 
 The first construct to be cloned and expressed was of a lectin with a C-terminal 
ELP fusion.  This design then laid the platform for further development of the constructs.  
The following are the design considerations and cloning methods employed to produce 
the first construct. 
DESIGN 
A lectin from Ralstonia solanacearum (RSL) was selected for its size and 
functionality.  A bacterial lectin of 9.9 kDa is small and amenable to expression in a 
bacterial host.  Furthermore, as a bacterial lectin, minimal codon optimization was 
necessary compared to that of plant or mammalian lectins.  In its natural form, this lectin 
forms a trimer, forming six binding sites with affinity to fucose
5,6
.  Fucose is a prominent 
biomarker in many diseases, such as certain cancers, liver disease, rheumatoid arthritis, 
Alzheimers disease, cystic fibrosis, and asthma
7-10




growing realm of therapeutic proteins, as core-fucosylation is found on the heavy chain 
of many antibodies, which makes it a desirable monosaccharide to target
11
.  
The ELP segment required additional modifications.  First of all, ELP’s are 
comprised of a pentapeptide repeat, VPGXG, where X is a guest residue of any amino 
acid except proline.  However, the guest residue dramatically affects the inverse 
solubility properties of this peptide
12,13
.  The majority of previous ELP purification work 
uses either the single substitute of valine or a block copolymer design with varying ratios 
of alanine, valine, and glycine.  The main specification to be optimized is the transition 
temperature.  If the transition temperature is too high, protein denaturation and loss of 
activity are likely to occur.  If the transition temperature is too low, the construct may 
precipitate inside the cell during culture cultivation and form unusable inclusion bodies.  
Moreover, if the construct is to be applied to industrial applications, heating a solution to 
a higher temperature would require an excessive amount of energy, thus increasing cost.  
A second specification to be met is the size of the ELP fusion.  If the ELP chain has too 
many repeats, it will likely burden the cell, hinder expression, and possibly sterically 
hinder the binding of the lectin domain.  In bacteria, decreasing ELP length from 90 to 20 
pentapeptides increased expression yield by 4 times
14
. 
In an effort to keep the ELP fusion small, but with a low transition temperature, 
previous work done by Meyer’s lab was consulted.  As shown by the predictive model 
and accompanying experiments from a study by Meyer et. al., Figure 2.1 illustrates the 
lowest transition temperature attainable is achieved by the ELP containing only valine as 










The Tt asymptote is at 24˚C, which is too low, as cultivation is usually done at 
about 30˚C.  However, this Tt occurs at 120 repeats of the pentapeptide, whereas 
reducing the number of repeats exponentially increases the Tt.  To obtain the most 
functional transition temperature, valine was selected as the guest residue.  Valine was 
also predicted to be successful based on its hydrophobicity, as shown in previous 
studies
12
.  A small library of varying pentapeptide repeats was experimented with to 
optimize ELP length to balance expression and Tt, as addressed in 2.3.1.2.  But the initial 
gene was designed with only 20 pentapeptide repeats, and thus is designated RSL-ELP20. 
The next section designed was a spacer or linker region between the two 
functional domains.  In fusion protein architecture, it is often crucial to incur some 
distance between two domains, so misfolding or interference does not occur
16
.  However, 
the linker itself can often restrict functionality, and varying lengths and flexibility must 
be investigated.  A popular flexible peptide linker often used is a glycine rich linker
17
.  




cassettes have been studied at length and seem to require a case by case analysis.  
However, some consistencies have emerged.  An average linker length between averaged 
sized protein domains is typically greater than 10 and less than 60 residues
18
.  With this 
in mind, a glycine rich linker of (GGGGS)2 was chosen to span the distance between the 
two functional domains.  This putatively allowed enough spacer between the two 
relatively small domains, while keeping the total size of the fusion protein to a minimum. 
Fusion order was a nontrivial decision made in the design as well.  As fusion 
order can control solubility, folding, and expression of recombinant proteins, it was 
investigated as well.  In a study done by Christensen, ELP fusions are designed as N- and 
C- terminal fusions.  In every case, the C-terminal fusion of the ELP was expressed to a 
higher level with higher probability of correct folding than that of the N-terminal ELP 
fusion.  It is speculated that this is due to lower levels of mRNA in the ELP to protein 
direction.  Intracellular degradation of the translated ELP portion is also a possible 
scenario resulting in decreased expression
19
.  In any case, it was decided that the ELP 
would be fused to the C-terminus of the lectin for optimal expression. 
To enable secretion, an N-terminal signal sequence was cloned before the lectin 
sequence.  This is further detailed in Section 2.3.2.1.   
Finally, the construct was adorned with an N-terminal His-tag marker after the 
signal sequence before the lectin.  This was done as an additional method of purification 
to confirm expression before functionality is confirmed.  It is also to enable near 
complete capture so expression levels could be quantified.  The final gene design is 






Tat  6xHis tag  RSL Linker  ELP20   
 
Figure 2.2 Gene design for RSL-ELP20 fusion. Blank boxes represent restriction sites. 
CLONING 
The gene was directionally cloned into a pQE80L derivative using sites BamHI 
and HindIII in the multiple cloning site. The plasmid map is shown in Figure 2.3.  The 
pQE80L vector is a high copy number plasmid with an ampicillin resistance marker and a 
multiple cloning site with an N-terminal 6xHis tag under the control of an inducible T5 








Figure 2.3 Plasmid map of designed plasmid pQE20. 
 
EXPRESSION 
After cloning of the synthetic gene into the plasmid was complete, the plasmid 
was transformed into a cloning host, E. coli K12 UT5600.  This strain, designated 
UT5600/pQRE20, was cultured.  To induce expression, the procedure described in 
ColE1 origin of replication 
Ampicillin resistance marker 
T5 promoter region 
Tat signal peptide sequence 
6xHis tag 




Materials and Methods was followed.  After allowing the culture to reach exponential 
phase, expression was induced by addition of isopropyl-beta-D-thiogalactopyranoside 
(IPTG) to the culture medium.  This was then allowed to cultivate for 24-48 hours.  The 
presence of the protein was confirmed by SDS-PAGE of the cell lysate, with broad bands 
identifying the expressed recombinant proteins, as visualized in Figure 2.4.  The apparent 
sizes of the ELP containing constructs were larger than the actual molecular weights, a 
result noted in other research
20,21
.  This disparity is likely due to the extended chain 
length of the ELP absent of any charged residues, which results in slower gel migration 
during electrophoresis.  It’s also important to note that the RSL in its native form 
associates into a trimer formation.  A unique band 2 or 3 times the size of the desired 
protein was also investigated, as trimer or dimer formation was likely.  Trimer 
association was optimal, as the maximum number of fucose binding sites were formed 
with full homotrimer association.  
 
Figure 2.4 Two samples expressing RSL-ELP20 (Lane 1 and 2) alongside a control 





2.3.1.2 RSL-ELP40 and RSL-ELP60 
 After successful design, cloning, and expression of the first construct, fusion 
proteins of similar yet altered structure could be pursued in hopes of optimizing the 
expression and functionality.  As discussed in Section 2.3.1.1, increased ELP length 
reduces the phase transition temperature, so fusion proteins with increased ELP length 
were cloned and investigated. 
CLONING 
In order to create this library of varying ELP length, a repetitive cloning technique 
was incorporated into the initial design of the gene, as is often done to create recursive 
ELP segments
22,23
.  By using restriction sites with compatible sticky ends, such as XhoI 
and SalI, the ELP region was clipped out of the gene and isolated by gel extraction. PCR 
was not utilized, as the GC rich region required for the pentapeptide repeats in the ELP 
made primer specification and amplification difficult. Instead, large amounts of vector 
were extracted via Maxi-Prep kits, and multiple digestions performed to isolate the 
required amount of ELP segment (about 300 base pairs in length). By digesting the host 
vector at only site SalI, a non-directional ligation occurred at the sites of the matching 
sticky ends comprised of TCGA/AGCT.  A schematic of this recursive cloning method is 




















Figure 2.5  Schematic of oligomerization of ELP gene. Step 1: Plasmid is digested at 
indicated sites.  Step 2: ELP20 containing fragments are collected, overhanging nucleotides 
are included in gray.  Step 3: Original plasmid is digested only at SalI. Step 4. ELP20 
fragments collected in Step 2 are ligated into the SalI site. 
 
As the ligation does not have a directional preference, at least 50% of the 
successfully ligated clones should be in the correct direction. This must be verified by 
sequencing or protein activity, as the sizes will be identical. Ligation at the mismatch 
sites of SalI of the vector and XhoI of the insert forms a non-restriction site combination 
of the two, thus successive cloning of longer ELP regions is possible at the single 
complete SalI site. The initial synthetic gene codes for 20 repeats of the pentapeptide, 
while cloning of repetitive regions allows for a library that includes repeats in multiples 
TCGA ELP20 AGCT RSL Linker SalI ELP20 XhoI 
TCGA ELP20 AGCT 
TCGA ELP20 AGCT 
RSL Linker SalI ELP20 XhoI 




of 20. Only 20, 40, and 60 ELP pentapeptide repeats were cloned, as longer polymers did 
not aid in significantly decreasing the transition temperature after 60 repeats. 
EXPRESSION 
To confirm the elongation of the ELP domain, the gene was expressed and the 
protein identified for validation.  As with the RSL-ELP20, the plasmid containing the 
RSL-ELP40 and RSL-ELP60 inserts were transformed into a cloning host UT5600.  The 
transformation procedure is described in Materials and Methods.  The colonies were 
screened and the potential candidates cultured.  The cultures were induced with IPTG and 
cultured for 24-48 hours.  The presence of the proteins was confirmed by SDS-PAGE of 
the cell lysate, with broad bands identifying the expressed recombinant protein.  The 
RSL-ELP40 construct has large band a little below 50 kDa, as seen in the crude fraction 
SDS-PAGE in Figure 2.6a.  Figure 2.6b is also the crude intracellular protein, but with a 
large band displaying expression of RSL-ELP60, at about 60 kDa. 
 











A) RSL-ELP40 and B) RSL-ELP60 
 
Cloning and Expression of VCNA-ELP40 
 To expand upon the initial design even further, a different lectin was employed 
for the fusion design.  By using the lectin with affinity to a different carbohydrate moiety, 
a broader range of application was achievable.  This also sets the stage for further 
development using a variety of lectins for the thermo responsive affinity design. 
CLONING 
After successful cloning of the fucose binding ligand, an alternative ligand with 
affinity to sialic acid was investigated.  To target sialic acid, a binding site from Vibrio 
cholera was isolated from a neuraminidase enzyme, NanH.  The binding site is 
comprised of 191 amino acids, requiring 573 codons for translation.  This lectin, named 
VCNA, was cloned for a VCNA-ELP40 fusion.  The majority of work was done with the 
40 repeat fusion of the ELP domain, given the suitable transition temperature and 
reasonable expression level, detailed in Chapter 3.  Due to this success, only the ELP40 
fusion was pursued. 
 The NanH enzyme has three primary domains.  The N-terminal domain is 
comprised of a sialic acid binding lectin.  This gene encoding this section was optimized 
for E. coli and synthesized by GenScript. 
 The primers were designed to transcriptionally fuse the desired linker to C-




PCR amplification of the synthetic gene, the linker was added, so the final insert included 
both the lectin and linker, as seen in Figure 2.7.   
 
Tat  6xHis tag  VCNA Linker   ELP40   
 
Figure 2.7 Gene design for VCNA-ELP40 fusion. Blank boxes represent restriction sites. 
 
EXPRESSION 
As with the other constructs, the plasmid containing the fusion insert was 
transformed into cloning host UT5600.  Colonies were selected by screening in the 
presence of ampicillin, and the plasmid size in these putative colonies was confirmed.  
These colonies were then cultivated and induced to express the protein of interest.   
In the case of VCNA expression, it was noted in previous literature that a heat 
shock induction method was used in tandem with traditional IPTG induction.  Although 
the protein band of the fusion protein was visible, attempts of purification using ITC to 
exploit the functionality of the ELP were unsuccessful.  It was hypothesized that poor 
folding of the VCNA domain resulted in misfolding of the ELP region.  In order to 
rectify the issue and aid in correct folding, the heat shock method, as described in 
Moustafa, was used at the time of induction
24
.  After allowing the culture to progress to 
an OD600 of 0.4, the culture flask is removed from the 37˚C incubator and submerged in a 
42˚C bath.  The culture is subject to this higher temperature for 20 minutes. This short 




recombinant protein.  After the heat shock, the culture is returned to room temperature for 
10 minutes before IPTG is added. 
 
2.3.2 Secretion of RSL-ELP Constructs 
 In order to become a cost effective option, the construct must be able to be 
resourcefully and economically produced and isolated.  By utilizing the fast growing and 
easily manipulated host, E. coli¸ the fusion protein can be expressed.  By utilizing 
translocation pathways and increased outer membrane permeability, the fusion protein 
can be secreted, and thus isolated by exploiting the thermo responsive nature of the 
construct.  This avoids inclusion bodies, sonication steps, and harmful protease activity.  
Two different secretion pathways were investigated to find the optimal production level. 
2.3.2.1 Tat Pathway 
After confirmation of expression, the construct containing plasmids were 
transformed into E. coli E609Y, a mutant strain of E609 containing a deletion of the lpp 
encoded lipoprotein.  This mutant strain confers a leaky outer membrane phenotype.  
When combined with a translocation pathway, such as the Tat dependent pathway, 
extracellular secretion is achieved
25
.  All constructs were designed to include the N-
terminal Tat signal sequence. 
 E609Y cultures containing plasmids with the constructed genes were induced and 
incubated at 18˚C.  Cells and extracellular milieu were harvested over the course of the 
48 hour cultivation.  The intracellular, periplasmic, and extracellular fractions were 
separated and analyzed to illustrate the localization of the constructs during cultivation 




present in the extracellular fraction, albeit in low quantities.  Each sample had secreted 
approximately 20 mg/L to 40 mg/L, as seen in Figure 2.8.  After SDS-PAGE analysis, 
displayed in Figure 2.9a, it was noted no desired protein was found in the extracellular 
portion at this time point.  However, by 24 hours, all constructs excluding the RSL-
ELP60 construct were discernible by SDS-PAGE in the extracellular portion.  This is 
observable in Figure 2.9a.  These bands indicating secretion continue to broaden over the 
course of the 48 hour cultivation, detailing an increased amount of protein secretion over 
time, as seen in Figure 2.9b.   
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Figure 2.9 Extracellular protein profile at A) 12 and 24 hours B) 36 and 48 hours 
 
As plotted in Figure 2.10, the amount of secreted recombinant protein reaches 35 
mg/L of culture for the smallest construct, the lectin with no fusion.  The RSL-ELP20 
and RSL-ELP40 constructs are secreted at levels of 30 mg/L and 18 mg/L, respectively, 
over the 48 hour incubation period.  No RSL-ELP60 was detectable in the extracellular 
milieu after 48 hours of cultivation.   





2.3.2.2 Sec Pathway 
In an effort to optimize extracellular secretion in a biological host, a different 
secretion pathway was also pursued.  It was a possibility that the translocation of a 
preprotein fusion would be more efficient than that of a folded and active protein. With 
this in mind, that Sec pathway for secretion was investigated. 
First, the fusion gene was digested from the pQTH vector at the BamHI and 
HindIII sites, comprising the entire gene sequence minus the Tat N-terminal signal 
sequence.  This was ligated into the pET20b+ vector at the same restriction sites to fuse 
to the Sec signal sequence. This new vector was transformed into E. coli BL21star(DE3), 
compatible with the T7 promoter.  The screened clones were induced, cultured, and 
fractionated to localize expression. 
These cultures were fractionated along with a control strain containing an empty 
plasmid.  Each localized region of three lanes in the SDS-PAGE below (Figure 2.11) 
contains first the control (pET20b+), followed by two separate cultures of the clone 
(pETRSL). The expression seems to be localized periplasmically; however, there doesn’t 
seem to be a difference between the control and the two clones. Little to no expression is 
visible.  Although it’s possible the dark band seen above the 25 kDa marker is the target 
fusion protein, further characterization did not confirm.  No distinct characterizing band 






Figure 2.11 Secreted protein profile via Sec pathway. Samples are control plasmid 
containing strain followed by 2 pETRSL containing strains. 
 
In an effort to possibly mediate or increase expression, I also transformed the 
cloned pETRSL vector into BL21(DE3)/pLysS. I also compared the expression of my 
protein in BL21star(DE3) to expression in BL21(DE3)/pLysS.  The addition of the pLysS 
vector allows tighter control over gene induction and expression.  Figure 2.12 is of the 








Figure 2.12 Periplasmic protein profile from Sec pathway combined with pLysS vector. 
Lane 1: MW Ladder Lane 2: BL21(DE3)/pLysS/pETRSL 
Lane 3. BL21star(DE3)/pETRSL 
 
Again, although there appeared to be a prominent band in the periplasm, the target 
was only localized to the periplasm, yielding very low expression when compared to the 
extracellular secretion of the Tat secretion pathway.  The pLysS plasmid attempt seemed 
successful, but the success of this pathway is overshadowed by the efficiency of the other 
secretion pathway.   
2.3.2.3 Cell Localization 
In using this relatively new method of protein secretion, it was important to 
monitor the location of the recombinant proteins in the process.  At this 12 hour time 
point, all desired proteins were localized to the periplasm, as noted in Figure 2.13.  As 
much as 4 mg/L of desired protein was localized to the periplasm in the case of RSL-
ELP20, with slightly lower levels of the other constructs, and a negligible amount of the 




at 12 hours as well.  While levels of RSL, RSL-ELP20, and RSL-ELP40 in the periplasm 
either decreased or remained relatively constant, SDS-PAGE analysis displays 
periplasmic build-up of RSL-ELP60, as seen in Figure 2.14.  Intracellular levels of all 
constructs were negligible except in the case of RSL-ELP40.  After 48 hours, it appeared 
as if a detectable (< 1 mg/L) of RSL-ELP40 was still localized to the cytoplasm.  The 
majority of this construct was detected as a band at about 150 kDa, which identifies with 
the trimer configuration of the RSL-ELP40 construct. 
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Figure 2.14 Periplasmic proteins after 48 hour cultivation of E609Y. 
Lane 1: Control containing empty vector, pQTH. Lane 2: E609Y expressing unfused lectin. Lane 
3: E609Y expressing RSL-ELP20. Lane 4: E609Y expressing RSL-ELP40. Lane 5: E609Y 
expressing RSL-ELP60, and periplasmic build-up of the construct. 
 
 
2.3.3 Secretion of VCNA-ELP Construct 
Based on the success of the Tat pathway in the E609Y strain, the production of 
the VCNA-ELP fusion construct was done solely using this method of extracellular 
expression.  Initially, a cultivation temperature of 18˚C was used, as this was the primary 
temperature used for the RSL-ELP expression.  There was concern that too high a 
cultivation temperature may cause the ELP in vivo to fold and precipitate, facilitating 
early inclusion bodies that are not translocated.  Two different IPTG concentrations were 
used to induce, and the total protein and recombinant protein levels were monitored at 24 
and 48 hours. 
 
 







A. Total Protein (mg/L) 
  0.1 mM IPTG 1.0 mM IPTG 
24 hours 374 217 
48 hours 510 331 
B. VCNA-ELP40 (mg/L) 
 
0.1 mM IPTG 1.0 mM IPTG 
24 hours 75 43 





With promising results of about 100 mg/L being produced, a similar cultivation 
was attempted at a higher temperature, hoping to promote cell growth, though possibly at 
the expense of protein production.  The same parameters were observed, though at a 
higher temperature of 30˚C after induction.  The results are summarized in Table 2.2 a 
and b. 
Table 2.2 Protein secreted by E609Y at 30˚C cultivation 
A. Total Protein (mg/L) 
 
0.1 mM IPTG 1.0 mM IPTG 
24 hours 312 144 





As visible from the quantification of both total protein and recombinant fusion 
protein, the increased temperature did nothing to improve the production levels.  It was 
concluded that a 48 hour, 18˚C cultivation after induction with 0.1 mM IPTG produced 
the best production levels of the VCNA-ELP40 fusion construct in E609Y. 
 
2.3.4 Endotoxin Presence 
By secreting the construct, it was hypothesized that avoidance of cell lysis would 
result in decreased endotoxin presence in the protein fraction.  Each strain (Y type and 
wild type) was cultivated according to the determined optimal conditions from the 
B. VCNA-ELP40 (mg/L) 
 
0.1 mM IPTG 1.0 mM IPTG 
24 hours 62 29 




previous experiment.  The working solution containing the recombinant RSL was 
measure for endotoxin units per volume (EU/mL) using a ToxinSensor Chromogenic 
LAL Endotoxin Assay Kit.  For the E609, this was the cell lysate, for the E609Y, it was 
the extracellular portion.  Although the E609Y measured 13000 EU/mL less than the cell 
lysate solution, the total units of endotoxin were still in the same order of magnitude for 
each sample, as seen in Table 2.3. 
 Each of these was then purified via His-tag affinity gel.  The purification yielded 
a large reduction of endotoxin in solution.  However, again, while the Y-type strain 
resulted in a lower EU/mL, the result is not drastically different.  The benefits with 
respect to reduced endotoxin levels were non-conclusive. 
 
Table 2.3 Endotoxin levels in protein fraction and after His-tag purification 
  Total Histag Purified 












In this study, lectin ELP fusions of varying ELP length were cloned, expressed, 
and secreted from the E. coli host.  These novel recombinant fusions were characterized 
and the dual functionality of the fusion was manipulated to illustrate a glycoprotein 
purification process using affinity precipitation. 
While affinity precipitation is not a new concept, the ability to produce an active 




introduced in the study.  No chemical coupling methods are required as in the case of 
Eudragit S-100 or other synthetic polymers
26-28
.  Avoiding the use of solvents and 
eliminating the loss of ligand due to incomplete coupling are beneficial for production on 
the industrial scale, and production in E. coli is a reputable method of production in 
industry today.  Extracellular secretion from this versatile host is also beneficial on the 
industrial scale for ease of isolation.  No large scale homogenization or cell lysis step is 
required to attain the ligand.  Secretion also aids in avoiding periplasmic located 
proteases, which minimizes proteolytic degradation and eliminates the requirement for 
protease inhibitors.  Production of this purification mechanism bacterially also greatly 
diminishes the cost of current affinity purification systems, such as affinity 
chromatography.  Avoiding expensive resins that require regeneration and that are easily 
fowled is a large cost benefit in downstream purification processes. 
However, while this secretion mechanism may be ideal for smaller constructs, it 
appears not to favor highly hydrophobic sequences.  The largest construct, RSL-ELP60, 
was not secreted to the extracellular milieu.  It is not likely a size limitation of the 
secretion mechanism, as the band pattern of the extracellular portion in SDS-PAGE 
analysis shows bands up to about 120 kDa in weight.  More likely, the halted secretion 
and localization to the periplasm of this construct is indicative to its higher 
hydrophobicity of the (VPGVG)60 sequence.  Active translocation of the fully formed 
and folded protein via the Tat dependent pathway is functional, as portrayed by the large 
build-up of RSL-ELP60 in the periplasm.  But the diffusion portion of the secretion 





While the Tat dependent translocation does not seem to discriminate against more 
hydrophobic proteins, as seen by successful translocation of RSL-ELP60, it does seem to 
have limitations.  While RSL-ELP40 is successfully translocated and secreted in 
desirable levels, there is still a detectable amount found within the cytoplasm of the cell.  
This is particularly noticeable as a lone band of about 120 kDa is detectable, illustrating 
the presence of the RSL-ELP40 trimer construct.  At first glance, the residual RSL-
ELP40 in the cytoplasm in trimers appears to be left behind due to size limitations of the 
translocation pathway.  However, the largest translocated heterologous protein in 
Streptomycetes via Tat is 146 kDa, while E. coli is generally accepted to translocate 10-
100 kDa using this pathway
29,30
.  The trimer formation is 84 kDa in actuality, which is 
within the range of known translocated proteins.  However, upon forming the trimer 
structure, it is possible the N-terminal signal sequence required for translocation may be 
shielded, leaving these trimers to remain in the cytoplasm. 
Finally, a variety of conditions were tested in order to improve the secretion and 
production levels of both of the fusion constructs.  Using this method, production of 
about 100 mg/L has been reached, which is a little low for industrial production cases.  
However, with some improvement, this platform still presents as a cost effective way to 








2.5 Materials and Methods 
Bacterial Strains and Plasmids 
Escherichia coli strain K12 UT5600 (F- ara-14 leuB6 secA6 lacY1 proC14 tsx-67 
Δ(ompT-fepC)266 entA403 trpE38 rfbD1 rpsL109 xyl-5 mtl-1 thi-1) was used as a host 
for all cloning steps.  Plasmid pQTAT containing an N-terminal TAT signal sequence 
was used as the host vector.  The fusion gene was synthesized by GenScript, and 
consisted of the lectin fused to 20 VPGVG repeats.  A 10 amino acid glycine rich linker 
was used to provide flexibility between the lectin and elastin fusion. 
Construction of Recombinant Plasmids and ELP extension 
 The synthetic gene was digested from the carrier plasmid with BamHI and 
HindIII restriction enzymes (NEB).  It was inserted in the multiple cloning site of pQTH 
at these same restriction sites, and ligated to form pQRE20.  A large amount of this 
plasmid was then cultivated and digested at sites SalI and XhoI to isolate the fragment of 
gene encoding 20 repeats of VPGVG.  The host vector, pQRE20, was then digested at 
SalI, revealing sticky ends compatible with both XhoI and SalI restriction sites of the 
insert.  The product was plasmid pQRE40, a fusion of a lectin to 40 repeats of VPGVG.  
This was repeated to produce plasmid pQRE60.   
Protein Expression 
E. coli strain E609Y
25
 was transformed by heat shock at 42˚C for 1 minute 
followed by a regeneration incubation in LB media at 37˚C for 1 hour.  The resulting 




A single colony with the plasmid carrying the synthetic gene was selected and cultured in 
3 mL LB broth and ampicillin overnight at 37 C and 250 RPM.  This seed culture was 
used to inoculated 100 mL LB broth culture containing ampicillin to an OD600 of 0.1.  
This larger culture was grown at 37C and 250 RPM to a cell density of OD600 of about 
0.4, at which point isopropyl-β-D-thio-galactoside (IPTG) was added to the culture to a 
final concentration of 1mM to induce the production of the fusion protein.  The 
cultivation temperature was then reduced to 18˚C and the cells were grown for an 
additional 48 hours. 
Heat Shock Induction 
 Cultures were grown first at 37˚C after seeding.  Upon reaching an optical density 
of 0.5-0.6 at OD600, the flasks were subjected to a heat shock of 42˚C for 20 minutes.  
The cultures were then removed and allowed to cool to room temperature for 10 minutes 
before the addition of IPTG to initiate protein expression.  The cultivation temperature 
was then reduced to 30˚C and the cells were grown for an additional 48 hours24. 
Fractionation 
 The extracellular fraction was collected as the supernatant after pelleting the cells 
of 10 mL of culture media.  This cell removal was done with centrifugation at 6,000g at 
4˚C for 25 min.  The extracellular milieu was concentrated for further analysis using 
centricones and centrifugation at 4,000g for 10 minutes.  This was repeated until a 
workable concentration was reached.  Periplasmic and cytoplasmic fractions were 




San Diego, CA).  A ten milliliter culture was harvested by centrifugation and re-
suspended in 5 ml of shock buffer solution comprised of 30 mM Tris–HCl, pH 8.0, 20% 
sucrose, and 1mM EDTA.  The cell suspension was incubated at room temperature for 10 
min and pelleted by centrifugation at 6,000g at 4˚C for 10 min. The cells were re-
suspended in 0.5 ml ice-cold 5 mM MgSO4 and incubated on ice for 10 min. The cells 
were pelleted by centrifugation as before, and the supernatant was collected as a 
periplasmic fraction. The pellet was re-suspended in 1 ml phosphate buffered saline 
(PBS) solution, sonicated, and centrifuged at 6,000g at 4˚C for 20 min.  The supernatant 
was saved as a cytoplasmic fraction. Each fractionated sample was analyzed using 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) or enzymatic 
activity assays. 
Isolation with Affinity Chromatography 
 To ensure lectin binding activity, the fusion protein was purified using affinity 
chromatography with a Fucose Separopore® (Agarose) matrix, obtained from bio-
WORLD.  The crude protein solution was added to this matrix and equilibrated with 
PBS.  This mixture was kept on ice on an orbital shaker at 60 RPM overnight to allow for 
binding.  The unbound fraction was washed from the column with PBS, and the bound 
fraction was eluted from the column with an elution buffer of 0.1M fucose in PBS.  
Protein purity was assessed by SDS-PAGE. 




 The solution was heated to the transition temperature of the ELP in an Eppendorf 
Thermomixer for 20 minutes at 300 RPM.  The solution was then centrifuged at 16,000 x 
g for 1 minute.  The supernatant was removed, and the pellet resuspended in PBS or PBS 
with 0.5M NaCl.  The resuspended solution was chilled at 4˚C overnight to maximize 
resolubilization of the ELP constructs.  This chilled solution was centrifuged again for 5 
min at 16,000 x g for 5 minutes to remove unspecific precipitates, and the supernatant 
was collected as the purified protein fraction. 
Protein Quantification 
Protein concentration was measured by the method described by Bradford using a 
protein reagent dye (Bio-Rad), with bovine serine albumin as the standard.  
SDS-PAGE Analysis 
Each sample was combined in a 1:1 ratio with SDS sample buffer (10% SDS, 
10% b-mercaptoethanol, 0.3 M Tris–HCl (pH 6.8), 0.05% bromophenol blue, 50% 
glycerol), boiled for 5 min, and resolved by 12.5% (w/v) SDS–PAGE. Each gel was 
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AFFINITY LIGAND CHARACTERIZATION 
3.1 Abstract 
These novel recombinant fusions were characterized and the dual functionality of 
the fusion was manipulated to illustrate a glycoprotein purification process using affinity 
precipitation. The preserved functionality of the fusion protein was tested, along with 
varying parameters to ensure robustness.  The RSL-ELP fusions exhibited phase 
transitions at 80˚C, 45˚C, and 36˚C respectively to 20, 40, and 60 repeats of ELP 
pentapeptide.  The VCNA-ELP40 fusion exhibited phase transition at 51˚C.  Addition of 
salt resulted in depressed transitions temperatures.  In the case of the RSL fusion, trimer 
formation needed to be investigated.  As formation of the trimer complex doubles the 
number of binding sites, it was crucial to ensure heating, salt, and other external factors 
used in the purification process did not disrupt trimerization.  The sensitivity of 
trimerization was tested and deemed to not be easily susceptible to dissociation.  The bi-
functionality of this affinity precipitation tool is illustrated by purification of a model 
glycoproteins, horseradish peroxidase (HRP) and fetuin, using a simple method of 
temperature cycling and centrifugation.  Furthermore, the fusion protein is tested against 
high contaminant solutions and competing glycoproteins to test its robustness.  Using this 
purification scheme, 98 ± 2.8% recovery of the glycoprotein is achieved while 
maintaining activity of the purified model glycoprotein.  90± 8.6% recovery is achieved 





Fusion proteins have long been produced via genetic engineering or chemical 
conjugation techniques.  Often, the fusing of proteins is mean to exploit bifunctionality of 
the final product, possibly having a synergistic effect or additional benefits.  Sometimes 
fusion is done simply as a method to determine location, study conformational aspects, or 
elucidate evolutionary traits
1,2
.  In any of the possible cases, it is crucial that the designed 
protein not lose function due to the fusion.   
More specifically, ELP’s have been chemically conjugated to various different 
targets, resulting in ELP-drug fusions
3-5
.  In most cases, these fusions have been shown to 
both retain thermally induced aggregation properties as well as biological activity
6
.  
However, different variations, such as fusion order or linker length, can often 
detrimentally affect the activity or binding properties of the fused domain
7,8
.  Because of 
this, extensive characterization is required to confirm retained function of the multi-
domain construct. 
 Once it’s been confirmed that each domain retains the expected function when in 
the fusion construct, the fusion protein as a whole is tested for operational function.  In 
short, the thermo-responsive ligand is tested as a method to purify a glycoprotein.  
Various factors must be investigated in ensure a straight-forward, feasible isolation 
method can be utilized.   The transition temperature, salt concentration, and stability of 
the binding region must be within reasonable constraints to maintain the integrity of the 
target glycoprotein. 
In order to do this, a fucosylated model glycoprotein was chosen.  Horseradish 




performance and structure is well characterized, as well as methods for assaying activity.  
In its native form, it has 9 potential sites for N-glycosylation, 8 of which are typically 
(60%) core (α1-3) fucosylated
9,10
.  The dominant glycan is shown below in Figure 3.1.  






Figure 3.1 Dominant glycan present on HRP. 
 
Because this model glycoprotein has peroxidase activity, it’s possible to monitor 
activity found in each step of the purification process.  By doing this, it is ensured that a 
biologically active product is available at the final step of the purification.  Furthermore, 
it helps localize where the most protein is lost, should it not all be targeted in the process.  
The short comings of the purification process as a whole can be more directly observed 
by monitoring activity. 
In addition to activity and maintained integrity of the target model protein, it is 
also important that this fusion protein have high specificity.  Particularly, if this construct 
is going to be applied to industrial or pharmaceutical applications, high purity of the final 
product is a must.  In some cases of novel purification methods, there is an aspect on non-
specific binding that occurs.  It is desired that this is kept to a minimum to avoid the 




fermentation.  Furthermore, in the case of lectins, there is promiscuous binding observed.  
In the case of the RSL lectin, while there is a high binding affinity for fucose, there is 
also a small, but measurable affinity for mannose.  Mannose is a very popular 
monosaccharide: a main building block comprising the main core of N-linked glycans.  If 
enough mannose is present in a sample, it’s possible it could out-compete the lectin’s 
preference for fucose.  Because of this, the final purity of the desired substance must be 
monitored, as well as extensive experiments performed pertaining to competitive 




3.3.1 ELP Functionality 
The transition properties of ELPs have been well characterized
11,12
, but the fusion 
of this peptide to various proteins has had differing effects on usually predictable 
characteristics.  While literature values for the transition temperatures of peptides ELP20, 
ELP40, and ELP60 were 80, 50, and 36˚C, respectively, inverse temperature cycling was 
performed at various temperatures to confirm the actual transition temperatures when 
these peptides were fused to the lectin monomer
13,14
.  The theory behind the selection of 
ELP lengths is based on the achievable transition temperature of the fusion construct.  
Ideally, a lower transition temperature would be advantageous, in an effort to not 





Initially, higher than predicted transition temperature were used to ensure the 
purification of the protein.  This was done to ensure initial functionality of the ELP 
domain.  To confirm the isolation of the fusion protein using ITC, the ITC product was 
visualized by SDS-PAGE analysis.  This was done for RSL-ELP20, RSL-ELP40, and 
RSL-ELP60, as shown respectively in Figure 3.2.  The second, higher molecular weight 
band is addressed in Section 3.3.2. 
 







Figure 3.2 SDS-PAGE of isolated A) RSL-ELP20 B) RSL-ELP40 C) RSL-ELP60 
 
The turbidity of the constructs in solution was monitored to determine the exact 
temperature range where aggregation occurs.  The transition temperature is typically 
defined as the point at which 50% turbidity has occurred
15
.  As shown in Figure 3.3, the 
transition temperature for the RSL-ELP40 construct was determined to be 45˚C, which 
could be depressed by addition of 0.5M NaCl to a transition temperature of 36˚C.  
Addition of 1.0M NaCl promoted precipitation of the RSL-ELP40 at room temperature.  




aggregation process was fully reversible and behaved similarly over the course of 
multiple cycles of temperature ramping and cooling. 
Furthermore, it was noted the addition of fucose had no effect on the transition 
temperature.  It was possible that, in the case of the trimerized construct, an additive 
property of the ELP’s could effectively lower the transition temperature.  It has been 
noted that increased concentration of ELP in solution lowers the Tt, so it’s possible to 
conclude that cooperative ELP’s in the same complex may reduce the over transition 
temperature of the trimer construct.  However, after complete trimerization of the 
constructs was confirmed with the addition of 0.1M fucose and SDS-PAGE, the turbidity 
study was repeated, with no varying results. 
 
 
Figure 3.3 Turbidity profile for RSL-ELP40 and RSL-ELP60, as well as influence of salt. 
 
This turbidity study was identically done to ensure the functionality of the ELP 
domain in the VCNA-ELP40 fusion construct.  The turbidity profile is shown in Figure 

































was carried out simply with PBS and varying salt concentrations.  A summary of the two 
most successful phase transition observations is illustrated below.  It was noted that the 
transition temperature of the fusion construct as a whole was higher than the RSL case.  
This is likely a result of using a larger lectin.  Where the RSL lectin is about 10 kD, the 
VCNA lectin is about 21kD, comprising of a larger portion of the fusion protein, while 
the ELP remains the same.  However, addition of salt still works as an effective additive, 
and lowers the transition temperature to about 38˚C. 
 
Figure 3.4 Turbidity profile of VCNA-ELP40, with and without addition of salt. 
 
In observing the precipitation characteristics of the ELP, it was also important to 
monitor the total concentration of ELP in solution.  Length of ELP has been linked to 
concentration of recombinant proteins in plants, where the maximum concentration 
peaked at 5-30 pentapeptide repeats
16
.  Also, higher concentrations of ELP protein lead to 
more efficient recovery during the ITC purification process.  This has been previously 
noted in fusion protein studies
13,17






























the solution as an enrichment strategy.  In this study, it was noted the concentration of 
ELP had to be above 0.5 mg/mL to see a distinct precipitation profile. 
 
3.3.2 RSL Functionality 
To ensure functionalization of the RSL in the fusion construct, the construct was 
purified using affinity chromatography with a fucose bound agarose column.  This matrix 
consists of cross-linked agarose beads with a fucose ligand separated by a five atom 
spacer.  By exploiting the fucose binding characteristics of the RSL, the constructs should 
be separable by this chromatographic method.  By allowing for binding and elution with 
a fucose buffer, the constructs could be isolated using this method.  Indeed, as depicted 
below by the SDS-PAGE gel in Figure 3.5, an (almost) single band was attainable using 
this method.  There is a small amount of smearing, which is attributed to the trimer nature 
of the lectin.  As the RSL is natively found in trimer form in the presence of fucose, the 
elution from the fucose affinity chromatography column was washed repeatedly in an 
attempt to remove fucose and elucidate a single band at the monomer molecular weight.  
While there is a prominent band seen in Figure 3.5, there is still some smear, suggesting 








Figure 3.5 SDS-PAGE detailing fucose affinity chromatography results. 
Lane 1: Effluent unbound to the column. Lane 2: MW marker. Lane 3: Isolated RSL-ELP40. 
Lane 4: Crude protein lysate. 
 
It appears that the RSL still managed to bind, and the smear appears to be a mix 
of a trimer and a dimer present in solution.  In order to investigate the stability and 
conditions under which this trimer was observable, the lectin was expressed without the 
ELP fusion. 
Once the RSL was expressed in singularity, without fusion, it was purified with 
the same affinity chromatography method used above.  The eluate was washed with DI 
water 3 times, and the apparent lectin band was shown to drop down to the molecular 
weight of the monomer, 10 kDa.  It was also noted that fusion constructs associated in 
trimer formations after the addition of fucose.  These trimers were observed with such 
stability that they remained in this configuration even after SDS-PAGE preparation and 
analysis, enduring addition of reducing agents, boiling, and electrophoresis.  This is 




sites are intra-monomeric and 3 binding sites are inter-monomeric.  To achieve 6 
complete sites of fucose association, the trimer configuration must be attained.  Although 
the lectin samples had been washed, they had been in the refrigerator for at least 24 
hours, and it appears trimerization occurs without the presence of fucose.  This suggests 
that the natural state and stability of the lectin is optimal in trimer form, and this 
association will occur in solution with no perturbation. 
Experiments were performed to ensure trimer association of the different sized 
constructs was favorable at a range of conditions.  Complete trimerization of all 
monomers occurred with all constructs in PBS at room temperature with the addition of 
fucose.  It had been hypothesized that incomplete association was likely in the case of the 
larger ELP constructs due to steric hindrance of the larger ELP fusions.  This association 
is facilitated with the addition of as little as 2 µM fucose, as suggested by the low 
detection limit in Kostlanova
18







Figure 3.6 Increased trimer presence of RSL with increased fucose concentration. Lane 1: 





It’s important that the ITC purification does not disrupt the formation of trimers, 
which are crucial for the targeting of the fucose containing.  To confirm this, I observed 
the trimerization induced by the addition of fucose at varying temperatures.  After 
isolating RSL-ELP20 constructs with ITC, I placed the samples at various temperatures, 
as shown below, for 15 minutes.  After taking a sample from each, I added, 0.5 M fucose 
to each while keeping each sample at its respective temperature.  I allowed 15 minutes for 
trimerization to occur, then took another sample.  It was also hypothesized that a certain 
destabilizing temperature existed, above which trimers of the RSL would not form and 
maximum binding efficiency would not be reached.  To test this, fucose was added to a 
solution of fusion constructs over a range of temperatures increasing up to the transition 
temperature of the ELP.  The lectin complex was monitored at each of these temperatures 
to observe if higher temperatures were detrimental to association.  In the most extreme 
temperature cases for the RSL-ELP20, where the transition temperature is 80˚C, 
trimerization was observed in all cases save the final stage where precipitation of the 
construct had already occurred.  This is seen in the last lane of Figure 3.7.  This suggests 

















1. 0 C 
2. 21 C 
3. 37 C 
4. 55 C 
5. 80 C 
 
6. 0 C with fucose 
7. 21 C with fucose 
8. 37 C with fucose 
9. 55 C with fucose 
10. 80 C with fucose 
 
Figure 3.7 SDS-PAGE depicting presence of trimers at different temperatures with and 
without fucose. 
 
As sodium chloride is often used as an additive to depress the transition 
temperature of ELPs in the purification process, it is important that increased NaCl not 
interfere with the association of the monomers of the RSL.  As the effect of up to 3.0 M 
NaCl in solution is investigated in Wood, et al., a similar study was performed.  High salt 
concentrations did not inhibit the trimer formation of the RSL, as pictured in Figure 3.8, 








Figure 3.8 Trimerization as a function of salt concentration. 
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3.3.3 VCNA Functionality 
The VCNA-ELP40 fusion construct was tested for retained lectin functionality.  
After ensuring ELP functionality, covered in section 3.3.1, the lectin portion was tested 
by targeting a model glycoprotein and a negative control.  The model glycoprotein used 
here was fetuin, a sialic acid containing glycoprotein.  VCNA-ELP40 was added to a 
fetuin solution in a 2:1 molar ratio of lectin to glycoprotein.  The predetermined ideal ITC 
method of 1M salt and transition temperature of 37 was used to isolate the fusion protein 
and the bound target, and the protein was eluted from the lectin using 2mM sialic acid 
solution.  If the lectin is functional, an isolate of the fetuin should be attainable, while 
only a single band of VCNA-ELP40 should be seen after attempting to isolate the asialo 
fetuin.  As seen below in the SDS-PAGE analysis of the purification in Figure 3.9, fetuin 
was isolated.  Of course, not all the fetuin was removed from solution; the ratio of 2:1 
was not sufficient in targeting all the desired glycoprotein.  However, this capture 
efficiency is further explored in Section 3.3.4.4.  This ensures the VCNA lectin domain 








1. Fetuin stock solution 
2.Uncaptured fetuin 
after VCNA and ITC  
3. Isolated VCNA after 
fetuin purification 
4. MW ladder 






Figure 3.9 Purification of fetuin with VCNA. 
 
3.3.4 Glycoprotein Purification with Model Glycoprotein 
To illustrate the functionality of this fusion protein, the constructs were used to 
isolate a fucose containing glycoprotein, horseradish peroxidase. Horseradish peroxidase 
(HRP) was chosen as model protein, as it is core-fucosylated at eight out of nine 
glycosylation sites
10
.  At 44 kDa, HRP is easily detectable using SDS-PAGE analysis, 
and confirmation of retained peroxidase activity after purification is easily confirmed 
with a commercial assay. 
3.3.4.1 Purification with ITC 
This purification study was performed with constructs RSL-ELP20 and RSL-
ELP40.  After initial isolation from the cell culture, a purified solution containing the 
constructs was prepared with ITC.  HRP was added in a 1:1 molar ratio to the 
concentration of fusion protein.  This solution was kept on ice overnight to promote 
complete binding.  ITC protocol was used to purify based on the thermo-responsiveness 
of the ELP, and the recovery of the HRP and construct was confirmed by monitoring 
protein concentration.  This was done using a standard Bradford Assay and SDS-PAGE 
analysis, as seen in Figure 3.10.  Using the RSL-ELP20 construct, a recovery of 56% was 





Figure 3.10 SDS-PAGE of HRP isolation using RSL-ELP20. 
 
Retained activity after the purification process implementation was also 
monitored.  By comparing the activity of the HRP before and after the process, as well as 
HRP undergoing the same conditions, a relative activity was observed.  A sample from a 
mixture of ELP construct and HRP was diluted 100 times and measure for HRP activity 
of peroxidase over a 5 minutes period.  The mixture was submitted to a cycle of ITC or 
addition of salt to isolate the HRP.  After resuspending the pellet containing the ELP 
construct and bound HRP, a sample was taken and diluted, and the activity of the 
resulting remaining protein was compared to that of the initial mixture.  It was observed 
that heating of the HRP resulted in a dramatic decrease in activity, as seen in Figure 
3.11(a-b).  Therefore, the purification that required no heating, just addition of salt, 
retained the most activity (Figure 3.11c).  In fact, with this method, the HRP retained 
about 98% activity, which suggests that the quantity purified with this method is high as 





Figure 3.11 Relative activity of HRP at different stages of purification. 
 
3.3.4.2 Purification from High Contaminant Solution 
To observe the specificity in a high contaminant solution, HRP was purified from 
a cell lysate mixture.  With no other glyoproteins present in the solution, the RSL-ELP40 
construct was tested to ensure non-specific binding was not occurring.  E. coli whole cell 
lysate with protein concentration 10 mg/ml was mixed with target protein 0.25 mg/ml 


































































(18 µM).  After one cycle of ITC, followed by addition of fucose to precipitate ligand, 
HRP was obtained in highly pure form, shown as a single band (Fig. 3.12), suggesting 
that the quality of purified protein maintained even in the presence of large amount of 
protein contaminants and other cellular debris.  Additionally, SDS-PAGE analysis was 
run on the purified mixtures, and is depicted in Figure 3.12.  While the captured activity 
may read as high, it’s still possible that non-specific binding is occurring, and the final 
product is not pure.  To check for this, the SDS-PAGE analysis below was observed.  A 
very clean and specific purification of the HRP was obtained from the lysate mixture, 
showing both high yield and purity. Admittedly, some activity retained in the supernatant 
after precipitation suggests some HRP is lost in the purification process.  Further 
experimentation was required to determine whether it was never initially targeted or 
simply lost in the process. 
Figure 3.12. HRP isolated from a crude cell lysate solution. 
 
3.3.4.3 Competitive Glycoproteins 
However, the previous section only deals with proteins from a bacterial cell 




proteins, it is highly unlikely there were any competing glycoproteins in solution. To 
further illustrate that the purification is specific for fucose-containing glycoproteins, an 
experiment was conducted with fetuin used as a glycoprotein target competitor.  Fetuin is 
a non-fucose containing glycoprotein of size 48 kDa, isolated from fetal calf serum
19
.  
The experiment was carried out as described above except the target protein is fetuin.  As 
shown in Figure 3.13, fetuin appeared only in the soluble fraction after ITC (lane 2), and 
there was no fetuin present in re-solublized pellet (lane 3), indicating its inability to form 
complex with RSL-ELP40.  Another experiment was conducted with the glycoprotein 
mixture containing an equimolar ratio (0.1 M) of HRP and fetuin, HRP was recovered 
with no reduction of yield when compared to the case without fetuin addition (not 
shown). These results indicate that the presence of a non-fucose-containing glycoprotein 
did not interfere with the purification and the affinity precipitation is sufficiently specific 
to fucose containing glycoprotein.   
 
Figure 3.13 SDS-PAGE of fetuin purification, negative control. 
 
In a similar fashion, the VCNA-ELP40 was tested.  However, the VCNA lectin is 




a negative control.  VCNA was added to an asialo fetuin solution in a molar ratio of 2:1 
lectin to glycoprotein, and ITC was performed by both addition of 1M salt and a 
temperature increase to 37˚C.  A sample of the supernatant and resuspended pellet was 
analyzed with SDS-PAGE, as shown below in Figure 3.14.  The single band of VCNA 
seen in the third column shows no presence of asialo fetuin, suggesting the lack of sialic 
acid present on the glycoprotein ceases the binding and purification interactions.  
Furthermore, there was no decrease of asialofetuin present when comparing the original 
solution to the unbound, supernatant fraction, further supporting that no competitive 
glycoproteins are targeted unless they contain the desired monosaccharide. 
 
1. Asialofetuin stock solution 
2. Uncaptured asialofetuin after VCNA and ITC 
3. Resuspended VCNA pellet (no asialofetuin seen) 





Figure 3.14 SDS-PAGE of asialo-fetuin purification, negative control. 
 
3.3.4.4 Complete Capture 
To investigate a relationship between recovery yield and the amount of ligand 




1:20.  Results showed that recovery yield increased with the increase of ligand relative to 
the amount of target protein present in the mixture and full recovery was approached with 
15-20 molar excess of ligand.   As shown in Figure 3.15, it was observed that the relative 
activity obtained in a cell lysate mixture was lower than that of a purification done 
without additional proteins present in the starting mixture.  By adjusting the ratio of the 
ELP trimer complex to the amount of HRP in solution, a higher relative activity was 
obtained.   
The recovery yield in this case was 49±0.9%, slightly lower than the case without 
contaminating debris, suggesting no major impact on recovery yield by contaminants, 
illustrating the advantage of the affinity purification process.  Even at very low target 
protein concentration, the presence of cell lysate reduced the recovery of HRP only 
slightly, from 98 ± 2.8% to 90± 8.6%. 
 

























Additionally, this was done with the VCNA-ELP40 fusion protein in relation to 
the sialylated model protein, fetuin.  The VCNA binding portion, unlike the RSL lectin, 
does not form multimers, so with only 1 binding site per lectin, the ratio required was 
expected to be higher than previous RSL experiments.  Also, fetuin has, on average, 
about 13.6 sialic acid residues per molecule, which is also more than the previous fucose 
content of HRP experiments
20
.  Because it’s been hypothesized that the ratio is related to 
complete titration of lectin to target sites, the estimated the molar ratio for complete 
capture would be around 13:1 VCNA to fetuin.  To get a full profile, several ratios 
leading up to 13 were tested and observed.  As seen in the graph below, Figure 3.16, 
complete capture occurred around 10:1 VCNA to fetuin, which is better than expected, 
yet still fairly close to the predicted value. 
 


























After extensive characterization, it appears as if the fusing of the two functional 
domains did not disrupt the folding of either, as each retained the intended functionality.  
Furthermore, it was shown that an environmental change manipulating the functionality 
of one end did not disrupt the functionality of the other.  Specifically, the addition of salt 
or fluctuation of temperature to precipitate the ELP did not disrupt the binding domain of 
the lectin portion; the addition of fucose for RSL binding did not disrupt the transition 
characteristics of the ELP.  Having confirmed the effectiveness of the construct for its 
intended use, further experimentation could be followed for purification methodization. 
These constructs are then applied to a purification scheme to purify a model glycoprotein, 
horseradish peroxidase.  Overall recovery of about 56% was reached in the case of RSL-
ELP20.  This recovery could be increased using a number of variables.  First of all, it is 
possible that addition of the glycoprotein in an equimolar ratio is over loading the binding 
capacity of the lectin.  The trimerized form of the lectin has 6 binding sites in close 
proximity, and the HRP has a minimum of 8 fucose saccharides per protein.  It is likely 
that the high avidity of the lectin, due to the polyvalency of the trimer form of the lectin, 
is binding multiple times to the same molecule of HRP.  It is also possible that some form 
of aggregation is occurring, where one HRP is bound to several lectin, after which the 
sterics of the ELP prevent further association of these lectin to other HRP proteins.  
Optimization of this ratio must be done to ensure that 56% is indicative of the actual 




constructs.  Once this ratio was investigated, a capture efficiency of 98% was attainable, 
confirming the ratio hypothesis. 
However, these experiments were carried out using a pure solution of isolated 
HRP in a buffer.  As this holds little to no consequence for application, a contaminated 
solution, comprised of a cell lysate protein solution or competing glycoproteins, was 
spiked with HRP.  This would illustrate a more practical purification scheme.  The 
recovery of the HRP using the lectin-ELP construct was poor at first, which led to further 
investigation into the stability of HRP.  It was found through monitoring the activity of 
the HRP throughout the process that increasing the temperature was damaging the 
structural integrity of the enzyme.  To remedy this, salt was used to induce ELP 
aggregation instead of temperature.  It is beneficial to have this alternative precipitation 
method, so other fragile glycoproteins can still be targeted using this purification method.  
This expands the applicability of this construct to a wider range of less stable proteins. 
Once this salt instigation method was ascertained, the experiments pertaining to 
purification of HRP from a contaminant solution were done.  A similar relative recovery 
of about 90% was seen from the cell lysate solution, displaying minimal disruption of the 
lysate on the construct and purification method.  Similarly, with the competing 
glycoprotein, fetuin, no fetuin was targeted using this method, portraying a specific 
affinity to fucosylated glycoproteins.  No non-specific binding was seen in either 
instance. 
This thermo-responsible affinity ligand development is a platform for further 
variation.  But capitalizing on the range of lectins available, similar constructs can be 




amenable in the field of glycomics.  By utilizing this thermoresponsive ligand, a focused 
separation will be achieved, avoiding the lengthy and multi-step process of 
electrophoresis, blotting, extraction, and clean-up.  Fractionation of biological samples 
with respect to a biomarker, such as fucose, will aid in glycomic profiling of diseases and 
disease progression.  This is also a scalable process easily applicable to industrial scale 
purification.  The inexpensive production of the lectin-ELP fusion in a bacterial host 
avoids the costs of expensive affinity resins.  Affinity precipitation is a promising 







3.5 Materials and Methods 
Isolation with Affinity Chromatography 
 Fucose binding functionality within the fusions were tested with a Fucose 
Separopore® (Agarose) matrix, obtained from bio-WORLD (Dublin, OH, USA).  The 
crude protein solution was added to this matrix and equilibrated with PBS.  This mixture 
was kept on ice on an orbital shaker at 60 RPM overnight to allow for binding.  The 
unbound fraction was washed from the column with PBS, and the bound fraction was 
eluted from the column with an elution buffer of 0.1M fucose in PBS.  Samples from 
each stage of the process were collected and analyzed with SDS-PAGE. 
Inverse Phase Transition 
The phase transition was facilitated by one of two methods:  1. The solution was 
heated to the transition temperature of the ELP in an Eppendorf Thermomixer for 20 
minutes at 300 RPM.  2. The appropriate concentration of NaCl was added to solution, 
either promoting the precipitation in itself, or aiding in precipitation by proceeding the 
aforementioned heating step.  The solution was then centrifuged at 16,000 x g for 1 
minute.  The supernatant was removed, and the pellet resuspended in PBS or PBS with 
0.5M NaCl.  The resuspended solution was chilled at 4C overnight to maximize 
resolubilization of the ELP constructs.  This chilled solution was centrifuged again for 5 
min at 16,000 x g for 5 minutes to remove unspecific precipitates, and the supernatant 





The transition temperature of the constructs was determined 
spectrophotometrically in a 96-well microplate reader (Spectramax M5, Molecular 
Devices).  Each well contained 200 microliters of PBS with 0, 0.5, or 1.0 M NaCl with 
construct at a concentration of 5 mg/mL.  Temperature was increased (in 2°C increments) 
from 30 to 50°C and the absorbance at 310 nm was measured. 
SDS-PAGE Analysis 
Each sample was combined in a 1:1 ratio with SDS sample buffer (10% SDS, 
10% b-mercaptoethanol, 0.3 M Tris–HCl (pH 6.8), 0.05% bromophenol blue, 50% 
glycerol), boiled for 5 min, and resolved by 12.5% (w/v) SDS–PAGE. Each gel was 
detected by Coomassie blue staining (Bio-Rad). 
Peroxidase Assay 
 For peroxidase assay, a solution of 0.0017 M hydrogen peroxide was prepared by 
diluting 1 mL of 30% hydrogen peroxide to 100 mL with DI water.  1 mL of this solution 
was further diluted into 50 mL of 0.2 M potassium phosphate buffer pH 7.0.  A 0.0025 M 
4-aminoantipyrine solution was prepared in 0.17 M phenol solution.  The hydrogen 
peroxide solution and aminoatipyrine solution were mixed 1:1 ratio, and diluted 
horseradish peroxidase was added.  Absorbance of the resulting mixture was measured at 






 The purification of HRP from a “contaminant” solution was done with a cell 
lysate mixture.  A 50 mL culture of E. coli was grown to an OD of 1 then centrifuged to 
collect a cell pellet.  This pellet was separated from the supernatant and resuspended in 5 
mL of PBS.  After the addition of 0.1mM phenylmethanesulfonyl fluoride (PMSF) to 
inhibit protease activity, the pellet was subject to sonication.  The lysed cell debris was 
collected by centrifugation, and the remaining supernatant was measure for soluble 
protein concentration.  This supernatant was spiked with HRP for the experimental 
amount and used as the high contaminant solution. 
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METHOD OPTIMIZATION WITH SOYBEAN PEROXIDASE 
4.1 Abstract 
Effective methods for isolation and purification of glycoproteins and other 
glycoconjugates are important to biopharmaceutical industry and diagnostic industry. 
They are also critical to an emerging field of glycoproteomics aimed to understand 
structure and function relationships of glycans. Previously, we reported development of 
thermal-responsive affinity ligands by fusing elastic like polymer (ELP) to a bacterial 
lectin. In this work, we apply the newly developed affinity ligand in an affinity 
precipitation process to isolate fucosylated soybean peroxidase (SBP) from a dilute crude 
plant extract. Under optimal conditions, one step binding and precipitation resulted in 
>95% recovery yield directly from crude extract and a 22.7 fold purification. The SBP 
isolated using this affinity precipitation process meets or exceeds the quality 
specifications of comparable reagent grade products by Sigma. We showed that the 
recovery yield had a strong dependence on the molar ratio of ligand to target fucosylated 
protein, with a ratio of three being optimal, which could be predicted based on the total 
fucose content per protein molecule and the number of binding site per ligand molecule. 
The optimal condition for elution of target protein was determined and a relatively high 
concentration of cognate sugar for the lectin (1mM fucose) was needed for effective 
elution (≥80%). To regenerate the ligand, fucose bound at the binding sites was washed 




to regain much of the binding ability. However, a gradual decline of binding ability was 
observed after each reuse. In spite of the decline, we demonstrated that the ligand could 
be used for 10 times, giving an averaged 80% isolation yield based on initial input of 
soybean peroxidase.  
 
4.2 Introduction 
4.2.1 Soybean Peroxidase 
Plant peroxidases are used widely as research reagents. With their activity easily 
and inexpensively detected, they are included in numerous commercial diagnostic kits. 
They are also used widely in food processing and in waste water treatment
1,2
.  
Horseradish peroxidase (HRP), for example, has been used as a conjugate for CL-ELISA 
for detection of antibody-mediated binding events, N-de-methylation to produce food 
flavor, and in removal of dyes from polluted water
2-4
.  These many uses of HRP could 
well be replaced with the functionally equivalent soybean peroxidase (SBP). Moreover, 
since SBP is more thermal and environmentally stable than HRP, it can be used in 
applications requiring more harsh conditions than HRP can tolerate
5-7
. SBP could 
potentially be derived from soybean hull, a byproduct of the soybean industry
8,9
. 
However, as SBP exists in a complex plant crude extract with a low concentration of 3% 
of the total hull protein content
9
, it requires an efficient isolation and purification process 
to a suitable purity dictated by the target application.  A previous economic analysis 
concluded that, using liquid enzyme extraction as the method of isolation, the main cost 




cost barrier by concentrating the target protein early in the process and reducing 
processing volume by virtue of specific interaction of ligand and protein. 
 
4.2.2 Affinity Precipitation Process Optimization 
Previously, we reported development of novel thermal-responsive sugar-binding 
ligands by fusing a small bacterial fucose lectin with an ELP
10
.  In this work, we apply 
the fucose-binding ligand to isolate SBP, a fucosylated protein from complex plant crude 
extract. We demonstrate a one-step affinity precipitation process that achieves >95% 
recovery and a product quality surpassing commercial reagent grade.  In chapter 3, it was 
briefly addressed that modifying some basic parameters, such as ratio of ligand to target, 
result in dramatic increases in purification yield.  However, this is only one parameter in 
one step of a much larger process.  In order to effectively optimize the novel purification 
process that works in tandem with the fusion protein, it must be properly constrained by a 
variety of parameters at all steps.  Ratios, salt concentration, pH, elution buffers, and 
temperatures are often the focus of ELP purification systems
11,12
.  
An effective method of affinity precipitation was developed, which could be used 
to enrich a low abundant target glycoprotein from a complex mixture with a high 
recovery yield.  Although the method is only shown here for a fucosylated protein, it is 
conceivable that this method of purification can be extended to other glycoproteins by 
developing thermal responsive ligands with lectins specific to sugars other than fucose, 







4.3.2 Purification Method 
 The method used in tandem with the fusion construct is a simple, straightforward 
method derived by understanding the dual functionality of the fusion construct.  By 
outlining the process, the areas that require optimization can be pinpointed.  Furthermore, 
the specifications of the crude and final product can be investigated to give a clear 
illustration of the capability of the purification process. 
4.3.1.1 Process 
A schematic representation of the affinity precipitation process is shown in Figure 
4.1.  The purification is initiated by addition of the thermal-responsive ligand, RSL-ELP 
fusion protein, to the crude plant extract. The mixture is incubated at an ambient 
temperature (~25˚C) for 30 minutes to allow the lectin to bind to the fucose on the 
surface of SBP, resulting in formation of RSL-ELP-SBP complex.  This is designated as 
“binding” in the figure below.  Subsequently, the mixture is brought to 50˚C, the complex 
precipitates out of the solution within 3 minutes. The fraction of SBP activity captured by 
the ligand, calculated by subtraction of residual SBP activity left in supernatant from the 
total initial SBP activity, is taken as recovery yield.  The above process was developed 
using 50˚C precipitation, which takes advantage of SBP’s thermal stability. For proteins 
that are less thermal stable, the transition temperature could be lowered by including salt 
in the precipitation step. The RSL-ELP construct was determined to have a Tt of 45˚C by 
turbidity studies.  Addition of 0.5M NaCl resulted in a reduction of this temperature to 
about 35˚C.  Thus the method could be easily adapted to a wide range of proteins with 




After the soluble contaminants are centrifuged out, the SBP-ligand bound 
complex is resolubilized.  However, to consolidate steps, this resolubilization is done in 
an elution buffer.  This both allows for the target and lectin-ELP to become soluble, as 
well as allows for dissociation of the complex.  This elution buffer should now contain 
only the fusion protein and target glycoprotein.  At this point, another round of ITC is 
performed.  This precipitates the ELP portion, which is no longer bound to the target.  
The pellet that forms from the aggregation is the lectin-ELP only, and the SBP remains in 
the soluble fraction.  The pellet is collected via centrifugation, and either washed or 
simply added back to a crude solution for recycle usability.  The soluble fraction is 


















Figure 4.1 Purification method schematic. 
 
4.3.1.2 Natural Extract Characterization 
The initial crude soybean extract had a protein concentration of 3.2 mg/mL, and 
the initial peroxidase activity was 18.5 U/mg.  Ligand was added to the protein solution.  
Using molar ratio of ligand and target SBP of 3, precipitation at 50˚C the recovery yield 
of SBP was 95%. Using 1mM fucose in elution buffer resulted in 80% release of SBP, or 
isolation yield.  In a typical experiment, after the elution step, 420 U/mg soybean 
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peroxidase activity in the supernatant was measured, representing a 8.4 fold of 
purification.  A summary of purification was shown in Table 4.1.  The quality of product 
was further indicated by the RZ (Reinheiszahl) value, which is a ratio absorbance of 
A403/A275, a measure of hemin content. The RZ value was increased from 0.19 for 
soybean extract to 0.75 after affinity precipitation. Compared to specifications of Sigma 
product, the SBP from the affinity precipitation has a specific activity up to 7 fold higher 
and a RZ value higher than the specified minimum (Table 4.1). 
 






The product stream was further analyzed by SDS-Page, which showed 
significantly reduced number of bands present. While a single homogenous solution was 
not obtained, the target protein was significantly enriched in the product stream (Fig. 
4.2), corroborating with the 8.4 fold increase in specific activity.  It is likely the widened 
band representing the SBP is a result of the different glycoforms found in a natural 
solution. 
 
Crude Purified Sigma 
Total protein (mg) 3.8 0.16 -- 
RZ value 0.19 0.75 ≥0.5 





Figure 4.2 SDS-PAGE of crude soybean extract, purified SBP, and RSL-ELP40. 
 
4.3.1.3 Glycan Profile 
Additionally, total carbohydrate and fucose content of each purification step were 
analyzed.  This was done to show fractionation of the purified sample in preference of 
fucose.  Each sample was completely hydrolyzed, so glycans were broken down into 
monosaccharides.  Using HPAEC, the monosaccharide profile and compositions were 
measured. 
After purification, there was a significant reduction of both mannose and xylose 
content in the product stream which accompanied an increase in fucose content, as 
depicted in Figure 4.3.  The concentration of the fucose increased from 4% of the total 
sugar content to 12%, indicating fractionation in favor of fucose.  The other sugars were 
dramatically eliminated, dropping from 56% of the content to a little less than 5%.  This 
clearance of non-identified sugars was very promising, as it indicates clearance of high 















Figure 4.3 Fractional compositions of the monosaccharides 
 in the crude and purified samples. 
 
Notably the fucose content in purified sample was close to the level reported for 
purified SBP
13
, suggesting that a majority of fucose present in the sample are associated 
with SBP (Table 4.2).  Furthermore, the ratio of remaining sugars in the purified fraction 
was consistent with the determined ratio of present monosaccharides in the native SBP 
glycans.  These ratios are calculated by normalization to the 2 N-acetylglucosamine 
residues present on the core of every glycan of SBP.  From this, the respective ratios of 
the other monosaccharides are compared, as labeled in Table 4.2.  This strongly suggests 
no prominent other glycoproteins were present in the isolate solution.  Taken together, 
while a homogenous SBP was not evident, most impurity present in plant crude extract 
was removed and the product stream is significantly enriched with SBP, which should 





















Table 4.2 Molar ratios of detected monosaccharides compared to literature value of SBP 
glycans 
 Molar Ratios 
 Fucose GlcNAc Xylose Mannose 
Literature SBP
13 0.9 2 0.7 3.3 
SBP pure 1 2 0.9 3.4 
 
 
4.3.2 Ratio Optimization 
In Chapter 2, a ratio study was done with RSL-ELP40 and HRP.  Clear 
improvement of capture was demonstrated by monitoring the activity of the HRP in 
different fractions of the purification process.  In order to optimize the SBP purification 
process, this experiment was repeated with the new target glycoprotein.  As shown in 
Figure 4.4, the recovery yield is dependent on the molar ratio of ligand to SBP.  As there 
are two binding sites per lectin
14
, a theoretic low limit of ratio is 0.5:1, corresponding to a 
scenario that a single lectin molecule binds to two separate SBP protein molecules. As 
depicted in Figure 4.4, this ratio only resulted in a 20% recovery. This could be explained 
by steric hindrance that prevents a single lectin molecule from binding two fucose sugars 
on two separate SBP molecules. Increasing the ratio to 1:1, however, improved the 
recovery only to 50%, indicating the binding of lectin to target protein was not as simple 
as one ligand: one protein as the ratio would suggest. About 95% recovery yield could be 
achieved using a ratio of three, representing two molar excess for the ligand.  Since on 
average there are 5.6 fucose moieties per SBP
13
, this ratio corresponds to the case that all 
fucose present on the SBP are bound to lectin.   Further increase in ratio did not increase 




more free fucose to bind to excess lectin.  This study suggests that fucose on the same 
protein molecule binds preferentially than to fucose from another protein molecule.  This 
is a likely scenario, as often lectin exhibit avidity, or multivalency that preferentially 
targets nearby monosaccharides.
15,16 
The highest yield is achieved when all fucose are 
bound to lectins. Thus the ratio that gives a near complete recovery could be predicted by 
the number of cognate sugar on a protein.  The highest recovery of 95% with molar ratio 
of three is a significant improvement over our last report which requires 20 molar excess 




Figure 4.4 Recovery yield as a function of ligand to target ratio. 
 
To ensure that no loss of activity was occurring due to denaturation or inactivity, 
the SBP activity was also measured in the remaining crude solution after a round of 























observed in Figure 4.5 below.  The absolute activity, in U/mg, is reported for both the 
purified and unbound fractions. 
 
Figure 4.5 Purified and unbound fraction: reported as absolute activity measurements. 
 
4.3.3 Elution Step 
As shown previously in Figure 4.1, dissociation of protein complex to elute target 
protein and to release ligand is an essential step in affinity precipitation.  Various elution 
methods were tested for optimal release of ligand.  The elution step must effectively 
release the target from the ligand, or else there’s no way to isolate the glycoprotein.  
Furthermore, optimization is preferred so as to minimize the use of hazardous or 
expensive chemicals, while allowing for near complete release of the target glycoprotein.  
Different methods such as pH, solvents, and competitive binding buffers are investigated. 































The most effective method for ligand release for lectins is a buffer solution with 
cognate sugar.  As fucose is relatively expensive compared to other monosaccharides, 
minimizing its use is important for the SBP purification. We investigated the effect of 
fucose concentration on the ligand release. Shown in Figure 4.6 is SBP elution efficiency 
as a function of fucose concentration.  Elution efficiency is calculated based on the initial 
input of SBP at the beginning of an affinity precipitation experiment.  The resulting 
activity is compared to the initial peroxidase activity of the crude sample, thus the 
relative activity is reported as a fraction of the possible activity.  The remaining SBP still 
bound to the ligand is measured as well, and is denoted as “activity bound.”  This is 
activity found in the resuspended solution after a second round of ITC meant to isolate 
the RSL-ELP from the target.  Measuring this activity also ensures that no loss of activity 
occurs due to inactivation or inhibition from the ITC or elution process.  Of the range of 
fucose concentrations investigated, 1 mM of fucose released about 80% SBP from 
protein complex, based on activity measured in the supernatant. 
 
























4.3.3.2 Avidity of Partially Hydrolyzed Mannose 
In many lectin chromatography cases, often a cognate monosaccharide it used to 
elute the bound fraction.  In the case of the RSL lectin, where fucose is the primary 
target, it would be quite beneficial to substitute a more cost effective monosaccharide in 
the elution buffer, as fucose is typically about $25/g from common chemical companies. 
Mannose ($1.10/g from Sigma) is a cheaper and more viable option.  However, more of it 
is required to release the target glycoprotein from the affinity of the lectin, as the binding 
to mannose is 100 times less than that of fucose.  Experimentation and optimization is 
required to determine if this substitution is a viable economic or process improvement. 
So, using the procedure similar to that of the pH alteration, the elution step was 
performed with varying concentrations of mannose in the buffer.  Anticipating a high 
concentration requirement due to the low affinity of the RSL to mannose, the 
concentrations were 0.1, 0.5, 1, 1.5, and 2M mannose in PBS.  Again, the activity of the 
crude, first supernatant from purification, second supernatant after dissociation, and the 
remaining pellet were measured.  Using the ELP40 construct, it was noted that about 85% 
of activity was purified from the initial purification.  At this point, the pelleted construct 
and target protein were resuspended in the respective mannose solutions.  Following 
another round of ITC to isolate the ELP from the target protein, the relative activity of the 






Figure 4.7 Activity in each fraction using a mannose containing elution buffer. 
 
A phenomenon that is often discussed in tandem with lectin affinity is the avidity 
of lectin containing regions.  Avidity refers to the “association constant of a polyvalent 
interaction”
17
.  When there is an increased ligand density, the binding of one lectin to an 
open site can synergistically aid in the binding of a nearby ligand to another open site.  
Typically, this is described in terms of surface glycans, where the nearby lectins all 
associate together to glycans of close proximity.  It was hypothesized that the 
multivalency of the trimer complex would increase the avidity to a surface that provided 
multiple binding sites.   
 
Table 4.3 Isolation yield using mannose, mannan, or hydrolyzed mannan 




% w/v Molarity Mannose Mannan 
Hydrolyzed 
Mannan 
0.1 5.6 mM 26.1 ± 2.4% 5.6 ± 0.5% 34.5 ± 1.2% 

























The partially hydrolyzed mannan averages about 2.5 times better than that of 
mannose, and at much lower concentrations than required of mannose (56 mM vs. 1.0M)  
Also, the hydrolyzed mannan performs about 1 order of magnitude better than that of 
mannan alone, which does not provide many binding sites for the lectin, as the degree of 
polymerization is high. 
4.3.3.3 pH and Solvent Release 
As the RSL binds to fucose primarily via hydrogen bonding, it was hypothesized 
that release of SBP or other fucosylated substrate from the construct could be 
accomplished by addition of a solvent.  DMSO, isopropanol, and ethanol were tested in 
SBP purification from a crude protein solution using ELP40 and ITC.  DMSO and 
isopropanol did not yield sufficient results, but the ethanol release consistently 
maintained an activity of about 65% compared to the crude mixture. While this is 
relatively efficient, it is not performing as well as fucose.  A cost analysis will be done 
comparing this lower yield achieved with a relatively inexpensive solvent to see if there 
is any merit in using ethanol as a method of target protein release.  Low pH buffers (pH 
2.2 and 3) were most efficient in SBP release but resulted in the loss of SBP activity.  
Solvents such as ethanol, isopropanol, and dimethyl sulfoxide, were also tested but 





Figure 4.8 Activity of each fraction using elution buffers of varying pH. 
 
4.3.4 Recycling the Ligand 
As affinity ligand is possibly a major cost contributor in an affinity precipitation 
process, we investigated the possibility of its reuse. To this end, after each purification, 
the ligand was isolated from SBP by temperature-induced precipitation and resuspended 
in a fresh batch of crude soybean extract to test its reusability.   In preliminary 
experiments, decrease in recovery yield was observed beginning at the third re-use and 
the recovery yield fell to 25%.  The reason for this may be due to the residual fucose that 
still bound with ligand after each use and ligand release. To regenerate ligand, a wash 
step was added to the recycle procedure.  After the final precipitation step to isolate the 
target, the pelleted ligand was resuspended in 100 uL PBS solution and resolubilized, 
rinsing residual fucose from the ligand.  The wash solution was subject to ITC again to 
pellet the ligand for the next addition of crude, and the resulting wash fluid was analyzed 
























of recycle.  Figure 4.9 details the purification results of the SBP each time the RSL-ELP 
was recycled, and Figure 4.10 illustrates localization of all measured activity throughout 
the purification process.  The isolation yield averages at 81.4% over the course of 10 
recycles, but a steady decline is visible.  It is likely that this drop is due to lost RSL-ELP 
in the process or possible fouling of the affinity ligand over time.  Increasing SBP activity 
remains in the unbound fraction, suggesting it no longer is binding to the RSL-ELP40.  
Repetitive temperature fluctations may aid in the unfolding of the lectin after multiple 
recycles, so binding is lost.  These results showed that the affinity ligand can be reused 
for 8-10 times without losing binding functionality as long as a wash step to remove 
residual fucose is added between two purifications. The ability to reuse ligand is a unique 
advantage in the design of our affinity precipitation.   
 



























Figure 4.10 Localized activity in each fraction over the course of 10 recycles. 
 
Furthermore, the RSL-ELP can be recycled in previously extracted crude 
solutions to target any remaining SBP.  After the initial precipitation step, the majority of 
the target glycoprotein is found bound to the RSL-ELP, but often some activity remains 
in the supernatant.  These supernatants, before the recycle ITC, had activities remaining 
in them from the previous purification ranging from 17-22% of the original activity of the 
crude.  After purification was complete, the isolated fusion protein was recycled into this 
supernatant to bind to the remaining SBP.  After second round of ITC, none of the 
supernatants had activity above 0.17%, suggesting that the recycle, even with the 


























from the crude.  This suggests that SBP makes up 4.2% of the total crude, which is very 
close to the literature value of 3% SBP content in a crude protein extract.    
  
4.4 Discussion 
4.4.1 Purification Capability 
We demonstrated in this study a successful use of our newly developed thermal-
responsive fucose binding ligand in affinity precipitation for purification of soybean 
peroxidase from a complex plant crude extract, where the target protein is a minor 
component (~3%).  Under optimal conditions, one step binding and precipitation resulted 
in >95% recovery yield directly from crude extract and a 22.7 fold purification.  The 
product isolated using this affinity precipitation meets or exceeds the quality 
specifications of comparable products by Sigma.  We showed that the recovery yield had 
a strong dependence on the molar ratio of ligand to target fucosylated protein, with a ratio 
of three being optimal, which could be predicted based on the total fucose content per 
protein molecule and the number of binding site per ligand molecule.  The optimal 
condition for elution of target protein was determined and a relatively high concentration 
of cognate sugar for the lectin (1mM fucose) was needed for effective elution (≥80%). To 
regenerate the ligand, fucose bound at the bind sites was washed off with a pH buffer 
containing no fucose. This simple wash process allowed the ligand to regain much of the 
binding ability. However, a gradual decline of binding ability was observed after each 
reuse. In spite of the decline, we demonstrated that the ligand could be used for 10 times, 




Taken together, an effective method of affinity precipitation was developed, which could 
be used to enrich a low abundant target glycoprotein from a complex mixture with a high 
recovery yield.   
 
4.4.2 Economic Analysis 
Affinity precipitation is an attractive purification method largely due to low cost 
of the process.  Avoiding the use of expensive resins and chromatographic machines 
minimizes major expenses.  An assessment of the laboratory costs is included in this 
work to provide a demonstration of the cost effectiveness of this method.  All materials 
are purchased by Sigma.  This assessment is outlined in Table 4.4.  First, a cultivation of 
2 liters of E. coli was calculated for material costs.  From previous studies, assume a 
production of 18 mg/L of RSL-ELP40 construct extracellularly after 48 hours of 
cultivation.  Collection of RSL-ELP from the culture is simply done by temperature 
cycling the extracellular milieu.  For the SBP affinity purification process, assumptions 
are made concerning the crude protein extract.  SBP is 3% of total crude hull protein, and 
total crude hull protein is 0.5% of the total soybean hull.  The soybean hull is 5% of the 
total bean weight.  If 2.3 kg of soybeans are processed for the crude hull protein extract, a 
calculated 17.4 mg of SBP is putatively found in solution.  Assume addition of RSL-ELP 
in a 3:1 molar ratio with SBP. 
In calculating the value of this process, the market cost of purified SBP from 
Sigma is used.  Sigma sells SBP for $104.50 for 5 kU.  Assuming 75% purification of the 
SBP in solution, and the average units per milligram achieved, the worth of this process 




this is calculated after one purification round.  If the remaining 15% of SBP were to be 
extracted from the crude, an additional $38 would be gained, bringing gain to $71.59.  
Furthermore, this is without capitalizing on the recyclability of the construct.  Even 
assuming 75% purification efficiency with each cycle, and recycling a modest 8 times, 
the gain comes to $491.93.  Even at bench scale, the inexpensive nature of the affinity 
purification method yields great benefits, and has much potential for scale up and 
applicability to other target glycoproteins. 
 














A.) Total Production Costs  
  
E. coli cultivation 
 LB broth, Ampicillin, IPTG 32.10 
  Soybean protein extract 
 Soybeans, Acetone, Buffer 47.90 
  Process buffers 
 PBS, Elution buffer 1.14 
  Total Cost $81.15 
B.) Total Product Value  
  Value of SBP 
 Units SBP purified 5,481 
Value per kU $20.90 
  Total Value $114.55 
C.) Total Revenue  
  
With Recycle x 8 
 Soybean extract 383.21 
Buffers 9.18 
Income 916.42 




4.5 Materials and Methods 
Chemicals 
All chemicals were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) 
unless otherwise specified and were used without further purification.  Soybeans were 
purchased from a local farmers market. 
Fusion Protein Expression and Fractionation 
The RSL-ELP40 fusion protein was expressed in E. coli and obtained as 
described in Arnold et al. 2014.  A single colony of E. coli UT5600 transformant was 
selected and cultured in 3mL LB broth and ampicillin overnight at 37˚C and 250 rpm. 
This seed culture was used to inoculate LB broth culture containing ampicillin to an 
OD600 of 0.1. This larger culture was grown at 37˚C and 250 rpm to a cell density of 
OD600 of about 0.4, at which point isopropyl-b-D- thio-galactoside (IPTG) was added to 
the culture to a final concentration of 1mM to induce the production of the fusion protein. 
The cultivation temperature was then reduced to 18˚C and the cells were grown for an 
additional 48 hours. 
Periplasmic and cytoplasmic fractions were prepared according to the method 
described in the pETsystem manual (EMD Chemicals, San Diego, CA). A culture was 
harvested by centrifugation. The pellet was re- suspended in phosphate buffered saline 
(PBS) solution, sonicated, and centrifuged at 6,000g at 4˚C for 20 min. The supernatant 
was saved as a cytoplasmic fraction. 




 Soybeans were soaked in 10% (w/v) in 0.1 M potassium phosphate buffer (pH 
7.0) at room temperature overnight.  The hydrated hull was removed from the bean, and 
the isolated hulls were again soaked in the same buffer for overnight, then homogenized 
by vortexing for 2 minutes.  The mixture was centrifuged for 20 minutes at 4˚C at 13,000 
x g.  The supernatant was collected and concentrated about 20 times by acetone 
precipitation. 
Monosaccharide Characterization 
Monosaccharide concentrations were measured by Dionex analysis.  To analyze 
the crude carbohydrate composition, the glycans are first hydrolyzed.  The hydrolysis is 
achieved by addition of 6 N HCl to the protein mixture and heating to 121˚C for 45 
minutes.  After neutralizing with NaOH to a pH of 7, the sample was centrifuged for 30 
seconds at 15,000 g to removed precipitates.  The sample was diluted for analysis.   
The release monosaccharide samples were analyzed by High Performance Anion-
Exchange Chromatography (HPAEC) using a DIONEX system equipped with an ED50 
electro-chemical detector (Sunnyvale, CA).  Monosaccharides were separated on a 
CarboPac PA-20 column (Dionex). Detection was through pulsed amperometry.  
(waveform: t = 0.41 s, p = −2.00 V; t = 0.42 s,p = −2.00 V; t = 0.43 s, p = 0.60 V; t = 
0.44 s, p = −0.10 V; t = 0.50 s, p = −0.10 V) The mobile phase consisted of degassed 
solution A containing 100 mM sodium hydroxide and solution B containing deionized 
water. The mobile phase was pressurized with inert gas (He) to prevent interference of 
airborne carbon dioxide.   An isocratic method containing 2% buffer A and 98% buffer B 





 To measure the concentration of sugar in solution, a dinitrosalicylic acid reagent 
solution (DNS) assay of the solution was used (Rutter 2013)
18
.  A 1% reagent solution 
was used.  DNS solution was prepared as follows: 0.75% 3,5-dinitrosalycylic acid, 1.4 % 
sodium hydroxide, 21.6 % potassium sodium tartrate, 0.55 % phenol, and 0.55 % sodium 
metabisulfate, dissolved in water.  In order to determine soluble reducing sugar 
concentrations, 100 μL of sample was added to 900μL of DNS solution.  These mixtures 
were then boiled for 5 min, centrifuged at 15,000g for 5 min, and optical density of the 
supernatant at 550 nm was measured.  Reducing sugar concentrations were calculated 
using glucose as standards. 
Partial Hydrolysis of Mannan 
 Partial mannan hydrolysis was prepared mirroring the method of preparation of 
agar oligosaccharides (Joo 2003)
19
.  2 w/v% mannan in water was mixed 50/50 with 5% 
HCl.  This mixture was subject to 121 ˚C for 60 minutes.  The resulting partially 
hydrolyzed mixture was neutralized with NaOH. 
Acetone Precipitation 
Chilled acetone was added in a ratio of 5 to 1 to the crude protein solution.  The 
mixture was vortexed, then refrigerated at -20˚C for an hour.  The precipitates were 
collected by centrifugation at 6,000 x g for 15 minutes.  The acetone supernatant was 
removed, and the pellet was resuspended in PBS.  An SBP activity assay as performed to 




Inverse Temperature Cycling 
The transition temperature of the constructs was determined 
spectrophotometrically in a 96-well microplate reader (Spectramax M5, Molecular 
Devices, Sunnyvale, California). Each well contained 200 mL of PBS with 0, 0.5, or 
1.0MNaCl with construct at a concentration of 5 mg/mL. Temperature was increased (in 
2˚C increments) from 30 to 50˚C and the absorbance at 310 nm was measured. 
SBP Activity Assay 
For peroxidase assay, a solution of 0.0017M hydrogen peroxide was prepared by 
diluting 1mL of 30% hydrogen peroxide to 100mL with DI water. One milliliter of this 
solution was further diluted into 50mL of 0.2M potassium phosphate buffer pH 7.0. A 
0.0025M 4-aminoantipyrine solution was prepared in 0.17M phenol solution. The 
hydrogen peroxide solution and aminoatipyrine solution were mixed 1:1 ratio, and diluted 
horseradish peroxidase was added. Absorbance of the resulting mixture was measured at 
510nm over a 5 min. time period at 25˚C in a microplate reader, Spectramax M5 
(Molecular Devices). 








Samples were run in triplicate to calculate standard deviation of error. 
SDS- PAGE Analysis 
Each sample was combined in a 1:1 ratio with SDS sample buffer (10% SDS, 




glycerol), boiled for 5 minutes, and resolved by 12.5% (w/v) SDS–PAGE. Each gel was 
detected by Coomassie blue staining (Bio-Rad). 
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APPLICATION TO THERAPEUTIC PROTEIN 
 
5.1 Abstract 
The goal of this work was to illustrate the efficacy of the expanded platform of 
the designed purification method using relevant therapeutic glycoproteins of clinical 
interest.  By utilizing two lectin fusions sequentially in a novel multi-lectin affinity 
precipitation (MLAP) method, a pertinent glycoprotein, erythropoietin, could be targeted.  
By constraining the process conditions required for the VCNA-ELP40 construct, optimal 
purification conditions were determined as ITC at 37˚C and 0.5 M NaCl with elution 
conditions of 1 mM sialic acid containing PBS buffer.   Replicated culture conditions 
mimicking industrial production were derived using old CHO cell growth media spiked 
with target glycoprotein.  The isolation ability of the target from this imitation media was 
promising, with purification yields at 64 ± 3% using the VCNA construct and 87 ± 4% 
using the RSL construct.  However, upon obtaining the final formulation of Epogen for 
experimentation, high presence of human serum albumin (HSA), required further 
investigation into over abundant glycoprotein depletion.  In replicated high albumin 
solutions, depletion of high abundant proteins consistently ranged from 95-99% while 
enriching the product concentration in the isolate.  EPO in the replicated used CHO 









The area of downstream pharmaceutical purification stands to receive the greatest 
financial benefit with the development of an affinity chromatography alternative.  Over 
80% of the cost associated with therapeutic protein production is found in the 
downstream processing.  Despite a projected 48% general expansion of mammalian and 
microbial product production, the improvements in downstream processing, specifically 
the capacity of chromatography, are incremental.
1
  Similarly, for post-translational 
understanding, pre-analytical purification and concentration of the sample could also 
benefit from improvement. 
 In order to apply this affinity precipitation process to an industrially relevant 
situation, the fucosylated and sialylated glycoprotein erythropoietin was investigated.  
Erythropoietin (EPO) is a naturally occurring glycoprotein hormone produced by the 
liver or kidney.  EPO indirectly regulates the oxygen in the blood by modulating 
erythrocytes, and is used in clinical treatments of anemia since the 1980’s.
2–4
 Typically, it 
is given to treat people with anemia due to critical illness, such as cancer or kidney 
failure.  Due to its effectiveness, it became the single greatest drug expenditure paid for 






 The production and subsequent purification of specific glycoforms of this drug 
are extremely significant for efficacy.  Specifically, the N-linked glycans dictate the 
activity and half-life of EPO, affecting the biosynthesis, pharmacodynamics, and overall 
biological activity
2,6,7
.  On the three N-linked sites of glycosylation, the chief player in 
the altering the efficacy is more explicitly attributed to the sialic acid residues present
8,9
.  
This is an issue in the production phase, as CHO and BHK cells have specific, 
preferential carbohydrate motifs.  However, extensive research has been done on CHO 
cell production of EPO, as this is the current method of large scale production in use
10,11
.  
Various perturbations in media affect the number of multi-antennary glycan structures, as 
well as sialylation.  The target glycoprotein is secreted by the CHO cell into the 
extracellular matrix, from which it then must be purified. 
 Additionally, in the case of CHO cell cultivation, over-abundant glycoproteins 
also present with a unique issue in purification.  The high concentrations of these 
contaminants can mask the presence or targeting ability of certain purification methods, 
and a depletion method must be employed.  One such of these over-abundant 
glycoproteins is albumin, found in high concentrations in blood and serum.  Methods that 




The deliverable therapeutic protein must have consistent efficacy.  The glycans at 
all three N-linked sites are typically identical, although one or two can sometimes present 
with increased branching.  The most abundant glycan is shown in Figure 5.1.  
Additionally, the O-linked glycosylation site may carry additional sialic acid residues, but 











Figure 5.1 Glycan of erythropoietin, adapted from Wang et. al 2013 
 
To apply the optimized lectin-ELP affinity purification method to purification of 
the EPO from CHO cell media, a multi-lectin method was employed.  Within research 
utilizing lectin chromatography emerged a cooperative method of combining lectins 
capable of recognizing different glycan structures, termed multi-lectin affinity 
chromatography (MLAC).  MLAC has been useful in glycoprotein enrichment strategies, 
and offers a new platform by which to target and analyze a glycoprofile.
16,17
  By 
simulating this method of utilizing multiple lectins, a more targeted process is 
constructed.  By using a novel multi-lectin affinity precipitation (MLAP) approach, a 
target glycoprotein can be enriched from a crude, high protein content solution, such as 
the extracellular media from CHO cells.  As seen in Figure 5.1, the glycans present on 




employing both the RSL and the VCNA lectin fusion constructs, the therapeutic 
glycoprotein can be targeted and extracted via sequential precipitation steps. 
 
5.3 Results 
5.3.1 VCNA-ELP40 Process Optimization 
In order to proceed with the most efficient method for EPO isolation, the method 
using VCNA-ELP40 needed to be optimized as the RSL-ELP40 ligand had previously 
been (Chapter 4).  While optimal ITC conditions had previously been determined for 
VCNA-ELP40 (Chapter 3), elution conditions had not been investigated. 
5.3.1.1 Optimal SA Concentration for Elution 
As was performed with the RSL-ELP40 in relation to the SBP purification in 
Chapter 4, an elution experiment was done with the VCNA with respect to its model 
target, fetuin.  First, a cognate sugar was used at varying concentrations in the elution 
buffer, and the isolation yield was monitored as a function of sialic acid concentration.  
At first, an arbitrary 10 mM was used for release in these studies, which was an educated 
guess based on the Kd of the VCNA lectin. It was likely in excess, which is wasteful of 
resources and possibly harmful to certain protein due to the positive charge of the sialic 
acid.  In order to reduce the amount of excess SA used in the elution buffer, an 
optimization of SA concentration in the release buffer was tested.  Table 5.1 summarizes 






Table 5.1 Isolation Yield as a function of SA concentration in Elution Buffer 
Sialic Acid 
Concentration 
10 mM 1 mM 0.1 mM 0.01 mM 
Isolation 
Yield 
92 ± 4.6% 96 ± 4.8% 61 ± 6.1% 44 ± 4.4% 
 
 
At 0.01 mM, a fair amount of release was observed: about half.  However, it seems 
sufficient to use 1 mM, as this was generating the highest release, and therefore, highest 
overall yield.  Again, it’s possible that the higher concentrations, such as 10 mM, would 
be detrimental to the target glycoprotein, as SA carries a positive charge. 
5.3.1.2 Adjusted pH for Elution 
Again, in an effort to create a feasible and cost effective alternative, varying pH 
was investigated as a release mechanism.  Particularly due to the charged nature of this 
sugar and its relation to the binding properties of the lectin, it was very likely that altered 
pH would be effective in terminating the affinity between the VCNA and fetuin.  The 
elution was performed by resuspending the VCNA- fetuin pellet in McIlvaine buffers of 
pH 2.2, 3, 4, 5, and 6.  Isolation yield is as tabulated below in Table 5.2, but isolate for 
pH 3 and 4 were unreadable.   
 
Table 5.2 Isolation Yield as a function of pH of elution buffer 
pH 2.2 3 4 5 6 
Isolation 
Yield 
30 ± 6.0% -- -- 16 ± 3.2% 10 ± 2.0% 
 
In this case, it appears the low pH is responsible for impairing the fusion protein.  




was repeated several times with similar results.  At higher pH, the change is not enough 
to facilitate release, so low recovery is seen.  Because of the poor results shown in Table 
5.2, using a pH change to facilitate elution does not seem to be effective. 
 
5.3.2 Model Glycoprotein Purifications  
In order to confirm the presence of competing glycoproteins, the purification 
technique was first tested on the crude CHO media by spiking with the desire amount of 
target model glycoprotein.  The purpose of this was three-fold.   First, a balanced ratio of 
ligand to target based on previous experiments was used to ensure no loss of capture 
efficiency in the CHO cell media solution.   Secondly, the purified product was 
monitored to confirm no high abundance of competing glycoprotein contaminants was 
targeted.  Finally, other large bands in the crude were scrutinized to observe depletion of 
other significant contaminants. 
5.3.2.1 CHO media 
The used CHO cell media was run on SDS-PAGE, Figure 5.2, to identify the 
proteomic profile contained in the extracellular matrix.  Overall, while there were many 
visible bands over a broad range of weights and concentrations, the most prominent band 
was the presence of albumin.  The albumin was from the fetal bovine serum added to the 
media to promote the growth of the CHO cells, not a product from the cells themselves.  
The CHO cell media is spiked with 10% fetal bovine serum, which, according to the 







Figure 5.2 Used CHO cell media protein profile. 
 
5.3.2.2 VCNA-ELP40 and fetuin 
First, the VCNA-ELP40 construct was used to target a fetuin spiked media 
sample.  100 µL of extracellular CHO growth media was spiked with 18 µg of fetuin.  
VCNA-ELP40 was added in a ratio of 10 :1 to the fetuin, and performed ITC using the 
VCNA-ELP40 favored conditions (37C + 0.5 M NaCl).  The elution of the fetuin from 
the ligand was done with an elution buffer containing 2 mM SA in PBS, and the ligand 
was isolated with another round of ITC.  The SDS-PAGE of the fractions is shown below 
in Figure 5.3. 
 As depicted in the SDS-PAGE, the VCNA-ELP40 was successfully isolated using 
the ITC and elution methods.  No remaining fetuin is visible in the ELP ligand lane.  The 
unbound fraction is still predominantly albumin, with some variation of other 
contaminants seen at other molecular weights as well.  The purified fraction, which 
ideally would contain only fetuin, still shows the presence of some albumin.  Based off 
protein quantification, about 60 ± 3% of the fetuin was isolated.  The estimated purity in 




was measured as well.  The reduction of this abundant albumin ranges from 94-97% 
reduction from the original media.  This is a promising way to reduce highly abundant 










Figure 5.3 Fetuin purified from CHO cell extracellular media by VCNA-ELP40. 
Lane 1: Molecular weight marker. Lane 2: Purified fraction. Lane 3: Isolated VCNA-ELP40. 
Lane 4: Unbound fraction. 
 
5.3.2.3 RSL-ELP40 and HRP 
The ability of RSL-ELP40 to purify the model glycoprotein, HRP, from the used CHO 
media was also tested.   20 µg of HRP was added to the media, and RSL-ELP40 was 
added in excess.  I performed a purification using the favored ITC conditions (50˚C) and 
used an elution buffer of 1mM fucose.  The melting point of EPO is noted as 53˚C, so 
purification at 50˚C should not be detrimental to the structure
18
.  The ligand was 
separated from the HRP product, and ran this product, the ligand, and the unbound 
fraction on an SDS-PAGE for analysis, as shown in Figure 5.4.  Similar results were seen 




with the VCNA, where the target glycoprotein was successfully targeted, but there is a 
remaining band that is likely attributed to the large abundance of albumin.  It is 
noticeable that in the purified fraction, there is an RSL-ELP40 trimer band present.  The 
concentration of ELP in solution was presumably too low, and while some ELP was 
removed during the elution process, the low concentration of ELP resulted in incomplete 
precipitation, so some ligand is still present in the product stream.  The lower band 
represented in Lane 1 is indeed HRP, based on activity measurements.  The purified 
fraction is still in the elution buffer, so all ligand present will only be in trimer form.  This 
method resulted in an isolation yield of 87 ± 4%, and an albumin depletion of about 92%.  
Estimated purity in SDS-PAGE of the final product is about 40%, due to the remaining 
ligand in solution. 
Figure 5.4 HRP purified from CHO cell extracellular media by RSL-ELP40. 









5.3.3 Sequential Purification  
The multi lectin affinity precipitation process requires sequential lectin addition 
and ITC.  I began to test this method with the model glycoproteins before attempting it 
with the Epogen acquired from Amgen.  I spiked the used CHO media with both fetuin 
and HRP.  I then purified them sequentially, using RSL followed by VCNA. 
 The sequential purification was done with RSL, followed by VCNA.  The first 
SDS-PAGE panel below shows the ladder, unbound fraction, pelleted ligand, and purified 
product.  Again, there was some residual RSL-ELP40 in the final product, so I performed 
another ITC round.  The isolate is depicted in the 2
nd
 SDS-PAGE panel, which shows just 
HRP and a band of albumin.  Also in the second panel is the purification of the fetuin 
from the same sample of CHO media using VCNA-ELP40.   
Figure 5.5 Sequential purification of model glycoproteins from CHO media. 
Lanes 1 and 6: Molecular weight marker. Lanes 2 and 7: Unbound fraction. 
Lane 3: Isolated RSL-ELP40. Lanes 4 and 5: Purified HRP.  
Lane 8: Isolated VCNA-ELP40.Lane 9: Purified fetuin. 
 
 
Repeat ITC to 
remove RSL-ELP40 





5.3.4 Over-abundant Contaminant Depletion 
As visualized in the sections above, an unanticipated difficulty in isolating EPO 
from a CHO extracellular media is the large amount of albumin, both BSA and HSA, 
present in solution.  Over abundant glycoprotein depletion is a crucial step in many 
purification stages, specifically in the area of diagnostics.  Albumin in blood samples 
range from 34-54 g/L, and is the dominant protein, often obscuring the investigation into 
other lower abundant proteins. 
 In regards to the current experiment, albumin is present in both the CHO 
extracellular media as well as the final EPO formulation.  The CHO media is 
supplemented with 10% fetal bovine serum (FBS).  Of the total protein content of FBS 
(average 38 mg/mL), albumin is again the dominant protein (average 23 mg/mL, range of 
20-36 mg/mL).  As this is added to a final concentration of 10% FBS in media, the final 
media likely contains about 2.3 mg/mL of albumin.  The final formulation of EPO, 
according to the MSDS, contains 2.5 mg/mL of albumin, but only contains 0.084 mg/mL 
of EPO.  This is about 30 times more albumin than EPO present in the sample, and must 
be addressed before continuing on with purification.  An SDS-PAGE of the received EPO 




Figure 5.6 Amgen Epogen visualized on SDS-PAGE. 
 
According to the MSDS for the product, a 1 mL vial contains 10,000 units, or 
0.084 mg of total EPO.  The MSDS further outlines the excipient list, which is as 
follows: 10,000 Units epoetin alfa, albumin (human) (2.5 mg), benzyl alcohol (1%), 
sodium chloride (8.2 mg), and sodium citrate (1.3 mg) per 1 mL water for injection.
19
  
So, again, an over-abundant amount of albumin was visualized and perceived as a 
particular obstacle. 
In order to simulate this complication without wasting valuable product, the over 
abundant protein depletion studies  were performed with 40 ug of target protein, either 
HRP or fetuin, which in 400 µL samples gives a final concentration of about 0.1 mg/mL, 
similar to that of the EPO presence.  The 400 µL sample contained increasing amounts of 
albumin, and the total recovery as well as albumin depletion was monitored with 
increasing albumin in both the RSL and VCNA fusion cases. 
5.3.4.1 RSL performance in high albumin  
Using RSL-ELP40, the HRP activity could be monitored to determine a more 





RSL:HRP was added to the high albumin solution, as this is a sufficient amount to target 
the majority of the HRP.  This purification was done in 5 solutions of varying albumin 
content containing 0, 0.1, 1, 10, and 50 mg/mL albumin respectively.  This range spans 
from typical culture concentrations up to the excipient concentrations to seek a point of 
optimal or failure of purification performance.  ITC was performed at 45˚C, and eluted 
with 1 mM fucose, per the originally defined optimal conditions.  The final purified 







Figure 5.7 Purified HRP from high albumin solutions. 
It’s apparent that a visible amount of residual albumin is still present as low as with the 1 
mg/mL albumin solution, however it is greatly depleted.  To further inspect the 
purification of the HRP, the activity of this solution was measured, and is reported below.  
An estimate of reduced albumin is reported concurrently in Figure 5.8 to illustrate 









 Figure 5.8 Isolation yield and % albumin depleted as a function of initial albumin 
concentration (HRP) 
 
5.3.4.2 VCNA performance in high albumin 
The same experiment was repeated with the VCNA-ELP40 and accompanying 
model protein, fetuin.  A ratio of 10:1 VCNA ligand to fetuin was used.  ITC was 
performed by the addition of 0.5 M NaCl and heating to 37˚C, and elution was done with 
2 mM sialic acid in PBS.  The final purified forms are depicted via SDS-PAGE analysis 
below in Figure 5.9. 


















Aside from a Bradford protein quantification assay, there was not quantitative 
method with which to measure the fetuin present in the final isolate.  To corroborate 
estimates, the band intensity and Bradford assay results were compared to estimate the 
amount of fetuin isolated as well as residual albumin.  Results are summarized in Figure 
5.10, illustrating some loss of isolation yield with increasing albumin content.  However, 
the albumin depletion remained fairly high at about 95% depletion even in the highest 
case. 
 
Figure 5.10 Isolation yield and % albumin depleted as a function of initial albumin 
concentration (Fetuin) 
 
5.3.5 Purification of EPO 
After showing a combination of fairly successful purification yields (>80%) and 
high albumin depletion (>95%) using the lectin fusion proteins in the previous section, an 
attempt to directly purify EPO from a CHO cell media mix was performed with each 
lectin.  Unfortunately, with such limited sample, various constraints remain to be tested 













A 50/50 ratio of the EPO with the CHO cell used media was mixed to a final solution 
with volume 600 µL. 
 RSL-ELP40 was added in excess, and standard purification conditions were used 
for ITC and elution.  The gel below in Figure 5.11 depicts two dilutions of the final 
purified fraction, after elution and isolation from the ELP construct.  While the albumin is 
still a dominant band, there is a visible EPO band below the 37 kD marker.  Based on 
band intensity and corroborated with Bradford Assay measurements, 60 ± 3% 
purification yields were estimated.  Furthermore, monitoring the albumin intensity, the 
albumin depletion reached about 85%, similar to previous experiments using HRP as a 
target in high albumin solution.  
 
 
 Figure 5.11 Purified fraction of EPO from CHO cell media 
Lane 1: EPO isolated fraction low sample loading. Lane 2: EPO isolated fraction high sample 
loading. Lane 3: Molecular weight marker. 
 
Similarly, the same CHO cell media solution combined with EPO was prepared 
and purified using the VCNA construct.  The VCNA-ELP40 construct was added in 
















excess, and the standard purification conditions were used for ITC and elution.  The SDS-
PAGE analysis in Figure 5.12 does not show a purified fraction, as isolation of the EPO 
was not successful.  Instead, the EPO band seems to be located in the final VCNA 
section.  The lanes in Figure 5.12 are, respectively, the crude fraction, the first resulting 
supernatant of untargeted protein after 1 round of purification, and the final VCNA 
isolate.  Typically, the final VCNA isolate is a single band seen just below 50 kD; 
however, the discernable bands at the EPO molecular weight indicate that the final 
product remained with the construct.  The EPO was either not sufficiently eluted with 








Figure 5.12 SDS-PAGE analysis of VCNA fractions. 
Lane 1: EPO in CHO media. Lane 2: Unbound fraction. Lane 3. VCNA-ELP40 and visible EPO. 
Lane 4: Molecular weight marker. Lane 5. Failed purified EPO (only visible albumin). 
 
Further indication that EPO was indeed targeted is the reduced visibility of the 
EPO band from crude to first supernatant.  The samples are identical in concentration and 
loaded amount, except for the second lane has been treated with a VCNA-ELP40 
purification round.  The reduced EPO in the supernatant suggests that is was targeted and 




removed from the crude.  Based on protein quantification estimates, it seems about 42 ± 
5% of the EPO was removed and accounted for in the VCNA stream.  The isolated 
fraction, as seen in the final column, clearly portrays albumin depletion, upwards of 98%.  






5.4 Discussion  
The goal of this work was to illustrate the efficacy of the designed purification 
method using relevant therapeutic glycoproteins of clinical interest.  To give a good 
representative test scenario, the therapeutic glycoprotein, EPO, was obtained in final 
formulation, but submerged in a CHO cell used media solution.  Ideally, this would have 
acted as a realistic case for industrial EPO purification, with similar protein contaminants 
and concentrations. 
However, it’s clear that obtaining the EPO prepared as a medicinal deliverable 
yielded more difficulties than predicted.  First of all, the extreme excess of human serum 
albumin had not been accounted for in preliminary experiments, and although resulting 
tests in high albumin solutions were relatively successful, the albumin used in those 
experiments were bovine derived and less likely glycated.  The human albumin in the 
final formulation of EPO likely masked the target, and even with significant depletion, 
represented a large portion of protein in the putatively purified product.  Secondly, the 
small amount of EPO provided by Amgen only allowed for a few experiments, so 
continued optimization and varied conditions were not feasible.  The preferred method of 
analysis, SDS-PAGE, did not always yield an amenable detection limit for smaller scale 
purifications.  Limited experiments were done, resulting in merely a proof of concept 
design and purification. 
In spite of these obstacles, fairly promising results were obtained.  With regards to 
the preliminary tests of isolating HRP from high albumin solutions, auspicious yields 
were achieved.  It’s clear some purification efficiency is lost due to increased 




concentration sample containing 50 mg/mL of albumin.  About 98% of the albumin was 
depleted in this sample.  Since the final isolate is in a concentrated solution, the presence 
of the final albumin is still very significant, albeit greatly reduced.  In the case of using 
VCNA and fetuin in high albumin scenarios, similar results were obtained.  Again, 
isolation yield is affected, but less so than the RSL-HRP system.  However, the VCNA 
does a poorer job of albumin depletion, especially at the higher albumin concentration. 
Hopefully, by performing a sequential multi-lectin purification, using both RSL 
and VCNA sequentially would reduce the amount of albumin dramatically.  Assuming a 
modest reduction of 85% each time, a second round would leave final albumin 
concentrations at only 2.3% of their original levels.  However, these sequential methods 
were done only with the model glycoproteins, HRP and fetuin.  There was not enough 
EPO sample to sustain further MLAP experimentation. 
Finally, the small amount of EPO obtained was used in a proof of concept type 
purification.  EPO formulation was mixed with the used CHO medium and was purified 
using each of the constructs separately.  Purification was acheived at levels of 60 ± 2.9% 
and 42 ± 5% by the RSL and VCNA constructs, respectively, and resulted in albumin 
depletion of about 85% and 99%, respectively.  While this is somewhat below the 
anticipated isolation ability, it is not uncommonly low.  Works often report 15-16% 
recovery, and some methods with chromatography yield 42% recovery.
20-22
  This low 
recovery is often accepted with the assumption the purity is high, as purity is more 
valuable for a therapeutic product.  While the purity using this purification system does 




is designed for targeted, quick, and complete capture from high contaminant solutions, 
and relative to other published work, the lectin fusion method could be competitive. 
 
5.5 Materials and Methods 
Materials 
2 vials (10,000 Units/vial) of Epogen were generously donated by Amgen per 
Amgen Agreement #2014584977.   CHO cells and accompanying media was generously 
cultured and donated by Travis Meyer and Dr. Bao’s lab from Georgia Institute of 
Technology. 
Media Preparation 
Warmed 1x F-12 Media (with L-glutamine) to 37°C for ~ 1 hour along with 
50mL of frozen FBS. Added 50mL of FBS to 500mL of F-12 Media in cell culture hood 
to prepare 10% FBS CHO Growth Media. F12 media was stored at 4°C, and was warmed 
to 37°C 30 minutes before use in cell culture experiments. 
Thawing Cells 
 Removed 1mL vial of CHO cells (Brian Wile – CHO 5 – 105 cells/mL, frozen in 
2012) and thawed in 37°C water bath for ~10 minutes. Added cells to 9 mL of CHO 
media and centrifuged at 300xg for 5 minutes at 23°C. Aspirated the supernatant, 
resuspended in 12mL of CHO media, and transferred cells to a T75 flask.  Moved to cell 






 After 48 hours, cells were at ~90% confluence. Aspirated off media, and washed 
with 10mL of warm PBS (without CaCl2 and MgCl2). Aspirated off the PBS, and added 
1 mL of .25% Trypsin-EDTA. Let the cells sit in the trypsin solution for ~5 minutes, and 
verified the detachment via bright field microscopy. Added 9mL of F12 media and 
pipetted up and down to remove any weakly attached cells from the surface of the plate. 
Transferred all 10mL to 15mL conical tube and centrifuged for 5 minutes at 300xg at 
25°C. Aspirated off the media, resuspended in 9mL of media, and added 3mL of the cells 
to 3 different T75 flasks – this made CHO Passage 6. Added 9mL of media to each flask, 
and then placed in incubator (37°C, 5% CO2). 
 After 48 hours, cells were at 100% confluence. All of the steps below were 
completed in triplicate (once for each flask of CHO Passage 6). Aspirated off media and 
washed with 10mL of warm PBS (without CaCl¬2 and MgCl-2). Aspirated off the PBS 
and added 1.3 mL of .25% Trypsin-EDTA, and let sit for ~5 minutes at room 
temperature. Added 9 mL of warm F12 media, and pipetted up and down to remove 
weakly attached cells. Transferred to 15mL conical tube and centrifuged for 5 minutes at 
300xg at 25°C. Aspirated off the media, and resuspended in 8 mL of warm F12 media. 
Added 2 mL of resuspended cells to 18mL of warm F12 media in new T75 flasks, and 
placed in incubator (37°C, 5% CO2) to make CHO Passage 7. 
 After another 72 hours, cells were at 100% confluence. Removed 20mL of media 
from each (N = 12) of the CHO Passage 7 T75 flasks and transferred to glass container. 




at 1000xg for 10 minutes (25°C) to remove dead cells and cellular debris. Decanted the 
supernatant (leaving 1 mL left at bottom) and transferred to glass bottle. 
 
Freezing Cells 
 After harvesting conditioned media, took one T75 flask, and rinsed with 10 mL of 
warm PBS, followed by 2 mL of .25% Trypsin-EDTA, and let sit at room temperature for 
~5 minutes. Added 8mL of warm F12 media, transferred to a 15 mL conical tube, and 
counted cells using automatic cytometer. Centrifuged at 300xg for 5 minutes at 25°C, 
aspirated media and resuspended in 10% DMSO in F12 media. Transferred cells to 
cryovial, placed in freezer container, and stored at -80°C overnight. The next day, moved 
the cells to liquid nitrogen. 
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CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
DIRECTIONS 
6.1 Conclusions 
 The work presented in this dissertation accomplished three objectives stated in the 
introduction: 1) thermo-responsive ligands were designed and expressed extracellularly 
by E. coli, 2) the ligand and accompanying affinity precipitation method were 
characterized and optimized, and 3) the process was applied to relevant glycoproteins. 
  
6.1.1 Design and Production (Chapter 2) 
 The design and production of the thermo responsive affinity ligands was 
achieved.  First, a fusion protein with an ELP peptide fused to the RSL lectin was 
successfully cloned and expressed into E. coli for production.  Subsequently, two 
additional constructs with elongated ELP regions were designed and cloned using 
recursive oligomerization.   These were also successfully expressed in the bacterial host.  
Additionally, one fusion of VCNA lectin to the ELP peptide consisting of 40 
pentapeptide repeats was successfully constructed and expressed.  Of the four constructs, 
three were successfully secreted by utilizing the Tat dependent pathway in tandem with a 
mutant E. coli strain, E609Y.  Fractionation of the E. coli cell periplasm revealed 
localization of the largest construct, RSL-ELP60, to the periplasmic fraction, likely due 




constructs were successfully produced, and secretion by this method reached production 
levels of about 20-100 mg/L of recombinant protein over the course of 48 hours.  This 
allows for easy isolation of the desired protein, avoiding inclusion bodies, large scale 
homogenization steps, and the need for additional protease inhibitors. 
 
6.1.2 Characterization (Chapter 3) 
 After production of the 3 different length RSL-ELP ligands and VCNA-ELP 
ligand, various methods were used to ensure the retained functionality of each domain.  
First, the ELP domain was tested to ensure inverse solubility characteristics were still 
functional.  This was done first by performing inverse temperature cycling on the crude 
protein solution and confirming the presence of isolated fusion protein.  To more 
accurately determine the transition temperature, turbidity tests were employed, defining 
the transition temperatures of each of the constructs.  The RSL-ELP fusions exhibited 
phase transitions at 80˚C, 45˚C, and 36˚C respectively to 20, 40, and 60 repeats of ELP 
pentapeptide.  The VCNA-ELP40 fusion exhibited phase transition at 51˚C.  Further 
perturbations revealed this transition temperature could be depressed by the addition of 
salt to the ELP solution to a manageable 37˚C. 
 Lectin functionality was tested using one of two techniques.  For the RSL-ELP 
fusions, functionality was tested using affinity chromatography with a fucose agarose 
column.  Ability to purify the constructs based on their affinity to fucose suggests the 
binding domain of the lectin is still active and was confirmed.  The VCNA was tested by 




glycoprotein, and the isolation of the fusion ligand would result in isolation of the 
glycoprotein, displaying a functional lectin domain. 
 The multidomain fusion proteins were tested for the intended use: use as a method 
of glycoprotein purification.  The constructs were used to isolate horseradish peroxidase 
and fetuin, fucose and sialic acid containing glycoproteins, respectively.  Allowing for 
binding using the lectin functionality, the ELP domain was then exploited using inverse 
temperature cycling.  This resulted in the isolation of the glycoprotein along with the 
fusion construct.  This method was tested with competing glycoproteins and high 
contaminant solutions to ensure robustness.  Recovery yield of the target glycoproteins 
reached 98% and 95% for HRP and fetuin, respectively. 
 After characterization of the construct, the method itself was further investigated 
to optimize operating parameters and minimize energy and materials usage.  By using a 
determined ligand to taget ratio, 0.5 M NaCl in the binding buffer, and 1 mM fucose in 
the elution buffer, purification of a low abundance glycoprotein could still reach a yield 
of 95%.  Recycle studies were performed as well, maintaining an average of 81.4% 
recovery over the course of 10 recycles. 
 
6.1.3 Applications (Chapter 4 and 5) 
 Once the construct and method had been established, this purification system was 
tested using relevant glycoproteins to portray range of application.  First, purification of a 
robust peroxidase from soybeans from a crude, natural protein extract was investigated.  
By merely soaking the hulls in an aqueous buffer, adding the fusion constructs, and using 




recovery yield was about 95%, and the quality specifications were comparable to the 
reagent grade product previously sold by Sigma.  This purification method resulted in 
little to no inactivation of the target enzyme, and was performed using simple process 
steps, such as heating and centrifugation. 
 The method was then applied to a more industrial scenario to target a medically 
relevant glycoprotein.  Industrial production was mimicked by spiking used CHO cell 
media with Epogen obtained from Amgen.  The ability of the constructs to target EPO in 
a high contaminant solution was tested, while depletion of contaminants was also 
monitored. EPO in the replicated used CHO medium was targeted at levels of 60 ± 2.9% 
and 42 ± 5% by the RSL and VCNA constructs, respectively, and resulted in albumin 
depletion of about 85% and 99%, respectively.  A method of multi-lectin affinity 
precipitation was introduced and tested with model glycoproteins to show enhanced 
specificity and contaminant depletion. 
 
6.2 Significant Contributions 
 This dissertation provides significant contributions to the field of protein 
purification for improving glycoprotein targeting methods.  Major contributions were 
made in the development of affinity-ELP fusion ligands.  Whereas previous work 
employs direct fusion of the ELP to the target protein, the work presented in this thesis 
suggests a platform for a multi-use construct.  Previous use of ELP’s requires that the 
protein of interest be recombinant and transcriptionally fused.  Furthermore, this previous 






Alternatively, the work described in this thesis advocates the use of a separate, reusable 
ligand.  This not only circumvents the issue of a cleavage step, but allows this construct 
to be used with natural, unaltered target proteins.  Furthermore, the ligand can be 
recycled; thus extending the use and minimizing total cost. 
 In regards to the affinity domain, the development of the bacterial lectin was also 
a novel approach.  The vast majority of commercialized lectins are plant derived, with 
nominal consideration given to bacterial lectins.  However, given their small size 
respective to their plant and mammal parallel, they make an efficient substitute for this 
affinity ligand construct.  Moreover, use of a sugar binding affinity ligand expands the 
range of applicability of the ligand.  In other fusion work, effort has been limited to 
specific binding domains targeting a single protein of interest
4,5
.  But by utilizing a sugar 
binding module, the construct can be applied to a whole range of glycoproteins.  Again, 
this sets the stage for further development of a library of lectin affinity constructs, used to 
target a variety of glycoproteins. 
 Finally, the process itself demonstrates an elegant, simple purification process.  
With this work, affinity precipitation is extended to the purification of an important 
category of proteins: glycoproteins.  More importantly, the separation is based on the 
presence of a specific monosaccharide.  Further development of the method could lead to 
a large scale alternative for affinity chromatography.  Expression of the ligand by a 
bacterial host is a start to evolving an economic method of production, should this 
method be applied industrially.  It supplies a substitute to isolation of expensive binding 




dissertation could be applied to further advancement of this affinity precipitation method, 
yielding a simple, cost effective purification system. 
 
6.3 Recommendations for Future Directions 
6.3.1 Incorporation of smaller affinity domains 
 As this method is in the same vein as affinity chromatography, affinity 
precipitation could stand to benefit from some of the advances that have evolved with 
chromatographic needs.  Specifically, smaller ligands have been designed, and these 
ligands have been engineering to have a higher affinity toward the target.  For example, 
protein A is notable for its binding capacity for IgG, but a truncated form of this ligand 
reduces size and non-specific binding while increasing long term stability
6,7
.  In this same 
fashion, further investigation into binding kinetics and protein functionality could result 
in a smaller, higher affinity ligand.  This reduced size would decrease the metabolic 
burden on the cell during production and promote better binding during the purification 
process.  Furthermore, even though the number of binding sites increases when the RSL 
forms trimers, the trimer formation is just another parameter to be concerned about.  It 
would be more advantageous to engineer a single protein with multiple binding sites to 
increase binding efficiency while avoiding the steric hindrance of associated trimers or 
dimers.  This approach from a protein engineering aspect would greatly benefit the field. 
 




The work in the thesis pertained to the development of two ligands: a fucose 
binding lectin and a sialic acid binding lectin.  With merely these two designs, a variety 
of applications were addressed.  However, to further expand the range of applicability, an 
entire library of lectin fusions could be developed.  Investigation of different lectins has 
led to the discovery of their immense variety of diverse carbohydrate targets.  Not only 
are different monosaccharide sugar moieties targeted, but also branched and linear 
oligosaccharides with differing compositions
8,9
.  This would allow for specific isoform 
isolation capability.  With the ability to target based on glycan recognition, a wide array 
of applications could be pursued.  Furthermore, this expanded library of lectin fusions 
could participate in the MLAP purification scheme.  In the case of many MLAC 
applications, as many as five different lectins have been employed for glycan targeting.
10
 
This gives the ability to screen for glycosylation changes in biological samples, giving a 
more comprehensive look at changing glycomes.
11
  This could be achieved with MLAP 
as well, providing a new library of fusion constructs were designed for this application. 
 
6.3.3 Optimization using EPO 
Unfortunately, due to limited amount of product, optimization and constraints 
with the lectin constructs and proposed MLAP method could not be performed with EPO.  
Only a quick proof of concept, resulting in less than predicted purification yields, could 
be performed with the obtained samples.  While the ratio optimizations for the constructs 
and their targets were done on model glycoproteins, not enough sample was obtained to 
optimized these ratios with EPO as the targeted glycoprotein.  Furthermore, it appeared 




to the VCNA: EPO combination.  If more EPO sample could be obtained, further 




 Finally, in order for this technique to become industrially relevant, the process 
will need to be scaled appropriately and constrained using industrial scale parameters.  
First of all, the constructs would need to be produced on the order of grams instead of the 
current milligram scale presented in this thesis.  A larger culture volume would need to 
be employed, as well as some method for controlled temperature ramping and cooling to 
perform the ITC to collect the construct.  By design, the scalability should be relatively 
straight forward when compared to its counterpart, affinity chromatography.  By 
employing this in-solution method, flowrate constraints and diffusion constraints are 
avoided.  In tandem with these chromatographic drawbacks is an extended time scale, 
which is limited by the volumetric throughputs
12
.  The affinity precipitation method 
reduces this, though by how much would need to be investigated at a larger scale.  The 
recycling of the construct, though effective, does diminish over time, which would also 
need to be addressed at the larger scale.  While affinity precipitation provides a promising 
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